Document:

EX-10.12

 Exhibit 10.12 
 EXECUTION VERSION 
 CARIB LATAM HOLDINGS, INC. 

AMENDED AND RESTATED 
 STOCK OPTION AGREEMENT 
 THIS AMENDED AND RESTATED STOCK OPTION AGREEMENT
(the “Agreement”), made as of this 9th day of May, 2012, by and between Carib Latam Holdings, Inc. (the “Company”) and Thomas M. White 2006 Trust (the “Optionee”). 

W I T N E S S E T H: 
 WHEREAS, pursuant to a Stock Option Agreement (the “Prior Agreement”), dated as of April 5, 2011 (the “Date of Grant”), Carib Holdings, Inc.
(“Holdings”) previously granted the Optionee options to purchase shares of non-voting Class B Common Stock of Holdings (“Holdings Class B Shares”); 

WHEREAS, in connection with a corporate reorganization, (i) Holdings became a wholly-owned subsidiary of the Company, (ii) all
of the issued and outstanding Holdings Class B Shares were contributed to the Company, (iii) the Company assumed the Carib Holdings, Inc. 2010 Equity Incentive Plan and all options issued thereunder or subject to the terms thereof and
(iv) the Carib Holdings, Inc. 2010 Equity Incentive Plan was renamed the Carib Latam Holdings, Inc. Amended and Restated 2010 Equity Incentive Plan (the “Plan”); 

WHEREAS, on May 9, 2012, the Company paid a dividend to its stockholders of $7.41 per share; 

WHEREAS, the Board has determined that it is necessary and appropriate to adjust the exercise price of the options pursuant to
Section 12 of the Plan by reducing the original per share exercise price by the per share amount of the dividend; and 

WHEREAS, the Company and the Optionee desire to amend and restate the Prior Agreement in order to reflect the foregoing. 

NOW, THEREFORE, in consideration of the covenants and agreements herein contained, the parties hereto hereby agree as follows:

 1. Grant of Option. Subject to the terms and conditions set forth herein, the Company hereby grants to the
Optionee the right and option (the right to purchase any one Common Share hereunder being an “Option”) to purchase from the Company, non-voting Common Shares pursuant to the Tranche A Options ( “Tranche A
Options”) and Tranche B Options (“Tranche B Options”) at a price per share (the “Option Price”) and in the amount set forth on the signature page hereto (the “Option
Shares”). The Options granted hereunder shall expire ten (10) years following the Date of Grant. 

 2. Vesting. 

(a) General. Subject to the terms and conditions set forth herein, the Optionee will become vested in the Options as follows: (i)
Tranche A Options will vest in equal installments on each of the first five anniversaries of the Date of Grant, and (ii) Tranche B Options will vest at such time as the Investor IRR equals or exceeds 20% based on cash proceeds received by the
Investor; provided, that, Thomas M. White is then providing services to the Company or an Affiliate of the Company. 
 (b) Change in Control. In the event of a Change in Control, any Tranche A Options that have not become vested at the time of such Change in Control shall automatically become vested upon such
Change in Control. Except to the extent Section 2(d) below shall apply, any Tranche B Options that have not vested prior to, or become vested at the time of, a Change in Control shall continue to be subject to vesting in accordance with the terms of
this Agreement. 
 (c) Initial Public Offering. In the event of an initial Public Offering, all Options shall remain
outstanding and continue to vest in accordance with their original vesting terms as set forth in Section 2(a) above. 
 (d)
Complete Disposition of Investor Investment. Any Tranche B Options that have not vested prior to, or become vested at the time that, the Investor Investment has been fully disposed of by all Investors shall be cancelled for no consideration.

 3. Exercisability. 
 (a) General. To the extent vested in accordance with Section 2 above, the Options shall only become exercisable from and after the earlier of the occurrence of (i) a Change in Control and
(ii) an initial Public Offering. 
 (b) Change in Control: In the event of a Change in Control, the Options shall
become exercisable, to the extent vested in accordance with Section 2 above, and the Company may provide that some or all of the Options be automatically exercised on a cashless basis in connection with such Change in Control and the Optionee
shall be entitled to receive the excess of (i) the per share consideration to be paid in connection with such Change in Control transaction (whether in cash, stock or otherwise) and (ii) the Option Price; provided, that any Option
for which the Option Price exceeds the amount in clause (i) may be cancelled for no consideration. 
 4.
Post-Termination Exercisability. 
 (a) Any Termination. Unvested Options shall be cancelled for no
consideration upon Thomas M. White’s termination of service with the Company and its Affiliates ( the “Service Termination Time”) for any reason. 
 (b) Vested and Exercisable. To the extent the Options were vested and exercisable at the Service Termination Time, the Options shall remain exercisable during the following post-termination
periods: 
 (i) Death/Disability: Earlier of (A) one (1) year following such termination and (B) the
expiration of the Option Term. 
 (ii) All Other Terminations: Earlier of (A) ninety (90) days following such
termination and (B) the expiration of the Option Term. 
 (c) Vested and Not Exercisable. To the extent the Options
were vested but were not exercisable at the Service Termination Time, the Options shall be eligible to become exercisable and remain exercisable during the following post-termination periods: 

(i) Death/Disability: Later of (A) one (1) year following such termination and (B) thirty (30) days following
the occurrence of a Change in Control or an initial Public Offering but, in each case, no event later than the day prior to the expiration of the Option Term. 

  
 2 

 (ii) All Other Terminations: Later of (A) ninety (90) days following such
termination and (B) thirty (30) days following the occurrence of a Change in Control or an initial Public Offering but, in each case, no event later than the day prior to the expiration of the Option Term. 

(iii) If a Change in Control or an initial Public Offering has not occurred prior to the expiration of the Option Term, the Options
shall expire without becoming exercisable. 
 5. Method of Exercising Option. 

(a) Payment of Option Price. Options, to the extent vested, may be exercised, in whole or in part, by giving written notice of
exercise to the Company specifying the number of Common Shares to be purchased. Such notice shall be accompanied by the payment in full of the aggregate Option Price. Such payment shall be made: (i) in cash or by check, bank draft or money
order payable to the order of the Company, (ii) through a cashless exercise whereby the Company reduces the number of Common Shares issuable upon exercise with a value equal to the aggregate Option Price and withholding obligation,
(iii) solely to the extent permitted by applicable law, if the Common Shares are then traded on an established securities exchange or system in the United States, through a procedure whereby the Optionee delivers irrevocable instructions to a
broker reasonably acceptable to the Committee to deliver promptly to the Company an amount equal to the aggregate Option Price or (iv) on such other terms and conditions as the Committee may permit, in its sole discretion. 

(b) Tax Withholding. At the time of exercise, the Optionee shall pay to the Company such amount as the Company deems necessary to
satisfy its obligation, if any, to withhold federal, state or local income or other taxes incurred by reason of the exercise of Options granted hereunder. Such payment shall be made: (i) in cash, (ii) by having the Company withhold from
the delivery of Common Shares for which the Option was exercised that number of Common Shares having a Fair Market Value equal to the minimum withholding obligation, (iii) by delivering Common Shares owned by the holder of the Option that are
Mature Shares, or (iv) by a combination of any such methods. For purposes hereof, Common Shares shall be valued at Fair Market Value. 
 6. Issuance of Shares. Subject to the terms hereof, as promptly as practical after receipt of such written notification of exercise and full payment of the Option Price and any required
income tax withholding, the Company shall issue or transfer to the Optionee the number of Option Shares with respect to which Options have been so exercised (less shares withheld for payment of the Option Price and/or in satisfaction of tax
withholding obligations, if any), and shall deliver to the Optionee a certificate or certificates therefor, registered in the Optionee’s name. 

  
 3 

 7. Repurchase. In the event of the termination of Thomas M. White’s
service with the Company and its Affiliates prior to an initial Public Offering, the Company shall have the right, but not the obligation, to repurchase any or all Common Shares acquired by the Optionee upon exercise of the Options that have been
held by the Optionee for at least six months at the time of such repurchase (or such shorter time as is required to avoid adverse accounting treatment) at a price per Common Share equal to the per share Fair Market Value. 

8. Stockholder Agreement. Notwithstanding anything herein to the contrary, in no event will Common Shares be delivered upon
exercise of the Options unless and until the Optionee executes (or is already a party to) an Adoption Agreement pursuant to which Optionee will become bound by the terms and conditions set forth in that certain Stockholder Agreement, dated
April 17, 2012, as may be amended from time to time pursuant to the terms thereof, by and among the Company and the stockholders of the Company, including those terms and conditions applicable to Management Holders (as defined therein), which
in all events shall be within thirty (30) days following exercise of the Options. 
 9. Non-Transferability.
Except as otherwise permitted in accordance with Section 15(b) of the Plan, the Options are not transferable by the Optionee otherwise than to a designated beneficiary upon death or by will or the laws of descent and distribution, and are
exercisable during the Optionee’s lifetime only by him/her (or his or her legal representative in the event of incapacity). No assignment or transfer of the Options, or of the rights represented thereby, whether voluntary or involuntary, by
operation of law or otherwise (except to a designated beneficiary, upon death, by will or the laws of descent and distribution), shall vest in the assignee or transferee any interest or right herein whatsoever, but immediately upon such assignment
or transfer the Options shall terminate and become of no further effect. 
 10. Rights as Shareholder. The
Optionee or a transferee of the Options shall have no rights as shareholder with respect to any Option Shares until he shall have become the holder of record of such shares, and no adjustment shall be made for dividends or distributions or other
rights in respect of such Option Shares for which the date on which shareholders of record are determined for purposes of paying cash dividends on Common Shares is prior to the date upon which he/she shall become the holder of record thereof.

 11. Adjustments. In the event of any adjustment pursuant to Section 12 of the Plan that would adversely
affect the value of the Options granted hereunder or cause such Options to become subject to Section 409A of the Code, such adjustment may only be made with the Optionee’s written consent, which consent shall not be unreasonably withheld.

 12. Compliance with Law. Notwithstanding any of the provisions hereof, the Optionee hereby agrees that it will
not exercise the Options, and that the Company will not be obligated to issue or transfer any shares to the Optionee hereunder, if the exercise hereof or the issuance or transfer of such shares shall constitute a violation by the Optionee or the
Company of any provisions of any law or regulation of any governmental authority. Any determination in this connection by the Committee shall be final, binding and conclusive. 

  
 4 

 13. Notice. Every notice or other communication relating to this Agreement
shall be in writing, and shall be mailed to or delivered to the party for whom it is intended at such address as may from time to time be designated by it in a notice mailed or delivered to the other party as herein provided; provided,
that, unless and until some other address be so designated, all notices or communications by the Optionee to the Company shall be mailed or delivered to the Company at its principal executive office, and all notices or communications by the
Company to the Optionee may be given to the Optionee personally or may be mailed to him at his address as recorded in the records of the Company. 
 14. Non-Qualified Stock Options. The Options granted hereunder are not intended to be Incentive Stock Options or Qualified Stock Options. 

15. Binding Effect. Subject to Section 9 hereof, this Agreement shall be binding upon the heirs, executors,
administrators and successors of the parties hereto. 
 16. Governing Law. This Agreement shall be construed and
interpreted in accordance with the laws of the Commonwealth of Puerto Rico without regard to its conflict of law principles. 

17. Plan. Although this stock option awarded pursuant to this Agreement is granted outside the Plan, the terms and
provisions of the Plan (as may be amended in accordance with the terms thereof) are incorporated herein by reference and this Option shall be administered in accordance therewith, and the Optionee hereby acknowledges receiving a copy of the Plan. In
the event of a conflict or inconsistency between the terms and provisions of the Plan and the provisions of this Agreement, this Agreement shall govern and control. All capitalized terms not defined herein shall have the meaning ascribed to them as
set forth in the Plan. For the avoidance of doubt, this Agreement (and the Options granted hereunder) shall be treated as an Award under the Plan (and this Agreement, an Award Agreement thereunder), including without limitation with respect to
Section 12 thereof, except that the number of shares covered hereby shall not be counted against the share reserve set forth in Section 5(b). 
 18. Interpretation. Any dispute regarding the interpretation of this Agreement shall be submitted by the Optionee or the Company to the Committee for review. The resolution of such a dispute
by the Committee shall be binding on the Company and the Optionee. 
 19. No Right to Continued Service. Nothing
in this Agreement shall be deemed by implication or otherwise to impose any limitation on any right of the Company to terminate Thomas M. White’s service. 
 20. Severability. Every provision of this Agreement is intended to be severable and any illegal or invalid term shall not affect the validity or legality of the remaining terms. 

21. Headings. The headings of the Sections hereof are provided for convenience only and are not to serve as a basis for
interpretation of construction, and shall not constitute a part of this Agreement. 

  
 5 

 22. Signature in Counterparts. This Agreement may be signed in counterparts,
each of which shall be deemed an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. 
 23. Entire Agreement. This Agreement contains the complete understanding of theparties with respect to the subject matter hereof and supercede all prior agreements and understandings,
including, without limitation, the Prior Agreement. 
 [signature page follows] 

  
 6 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first set
forth above. 
  

			
	CARIB LATAM HOLDINGS, INC.
		
	By:	 	 /s/ Peter Harrington

	Name:	 	Peter Harrington
	Title:	 	President and Chief Executive Officer
	
	THOMAS M. WHITE 2006 TRUST
		
	By:	 	 /s/ Thomas M. White

	Name:	 	 Trustee

  

											
	 	 	 	 Number of Options
	 	  	Option Price	 
			
	 	Tranche A Options	  	 	 	22,500	  	  	$	2.59 per share	  
	 	Tranche B Options	  	 	 	22,500	  	  	$	2.59 per shareLicense Agreement

 Exhibit 10.1 
 ***Text Omitted and Filed Separately 
 with the Securities and Exchange
Commission. 
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2. 
 CONFIDENTIAL

 EXECUTION COPY 

LICENSE AGREEMENT 
 THIS LICENSE AGREEMENT (the “Agreement”) is entered into as of March 23, 2012 (the
“Effective Date”), by and between DSM FOOD SPECIALTIES B.V., a Dutch private corporation (“Licensee”), with its principal place of business at Alexander Fleminglaan
1, 2613 AX Delft, Netherlands, and VERENIUM CORPORATION, a Delaware corporation (“Verenium”), with its principal place of business at 4955 Directors Place, San Diego,
California 92121, USA. Verenium and Licensee are referred to herein collectively as the “Parties,” and each is referred to herein as a “Party.” 

WHEREAS, Verenium and Licensee have entered into that certain Asset Purchase Agreement dated
as of March 23, 2012 (“Asset Purchase Agreement”), pursuant to which, among other things, Verenium will sell to Licensee, and Licensee will purchase from Verenium, all of the assets of Verenium’s oil seed
processing business, including rights with respect to Purchased Products and Purchased Enzymes (as defined below), as further described in the Asset Purchase Agreement; 

WHEREAS, in connection with the Asset Purchase Agreement, Verenium desires to grant to Licensee, and Licensee
desires to obtain from Verenium, a royalty-bearing license with respect to Products (as defined below) for uses in specified fields on the terms and subject to the conditions set forth in this Agreement; 

WHEREAS, in connection with the Asset Purchase Agreement, Licensee desires to grant to Verenium, and Verenium
desires to obtain from Licensee, a royalty-bearing license with respect to Purchased Enzymes for uses in specified fields on the terms and subject to the conditions set forth in this Agreement; and 

WHEREAS, in connection with the Asset Purchase Agreement, Licensee and Verenium wish to agree to an arrangement
pursuant to which Verenium will perform specified research activities to create New Gene Libraries (as defined below) and provide access to the New Gene Libraries to Licensee on the terms and subject to the conditions set forth in this Agreement.

 NOW, THEREFORE, in consideration of the mutual covenants and promises
hereinafter set forth, the receipt and sufficiency of which the Parties hereby acknowledge, the Parties hereby agree as follows: 

ARTICLE 1 

DEFINITIONS 
 1.1 “Accounting Standards” means generally accepted accounting principles in the United States, or internationally, as appropriate, consistently applied and shall mean the
international financial reporting standards (“IFRS”) at such time as IFRS becomes the generally accepted accounting standard and applicable laws require that a Party use IFRS. 

 1.2 “Affiliate” means any entity that directly or indirectly
controls or is controlled by or is under common control with a Party to this Agreement. For the purpose of this definition and the definition of Subsidiary below, “control” means ownership, directly or through one or more Affiliates, of
greater than 50% (or such lesser percentage which is the maximum allowed to be owned by a foreign entity in a particular jurisdiction) of the shares of stock or other equity interests entitled to vote for the election of directors, status as a
general partner in any partnership, or any other arrangement whereby a Party controls or has the right to control the board of directors or equivalent governing body of a corporation or other entity. 

1.3 “[...***...]” means [...***...]. 

1.4 “Purchased Assets” shall mean all of the assets purchased by Licensee from Verenium pursuant to the Asset
Purchase Agreement. 
 1.5 “Audited Party” shall have the meaning set forth in Section 5.8(a).

 1.6 “BP” means BP Biofuels North America LLC, a Delaware limited liability company. 

1.7 “BP Field” means the researching, development, manufacture and commercialization (including without
limitation to make or have made, use or have used, practice or have practiced, improve or have improved, import or have imported, export or have exported, market or have marketed, distribute or have distributed, license, sell, offer for sale or have
sold) of lignocellulosic ethanol and other lignocellulosic biofuels and lignocellulosic bioproducts, lignocellulosic butanol and lignocellulosic diesel biofuels, including without limitation conversion of cell wall sugars and/or cell wall sugar
compounds into biofuels or bioproducts, and for the avoidance of doubt excludes starch to ethanol, starch to other biofuels and starch to bioproducts. 
 1.8 “Confidential Information” means any information and materials furnished or made available by one Party to the other Party, whether orally or in written, electronic or other
form. Confidential Information shall include the terms of this Agreement, and any scientific or technical information, technical data or specifications, testing methods, computer software, documentation, know-how, trade secrets, inventions, data,
processes, procedures, devices, methods, formulas, media, lines, reagents, compounds, protocols, research and development activities and results, product and marketing plans, customer and supplier information, and marketing and other proprietary
business information, whether or not patentable, including any such information that become known to the other Party during visits to the facilities of the disclosing Party. For clarification, all Purchased IP shall be the Confidential Information
of Licensee, and all Verenium Licensed IP and Verenium Reserved IP shall be the Confidential Information of Verenium. 

  

***Confidential Treatment Requested 

  
 2. 

 1.9 “Control,” “Controls,” or “Controlled’
means possession of the ability to grant the licenses or sublicenses as provided for herein (other than by virtue of any license granted pursuant to this Agreement) without violating the terms of any agreement or other arrangement with any Third
Party. 
 1.10 “Disclosing Party” means that Party that discloses or makes available Confidential
Information to the other Party. 
 1.11 “Enzyme” means any protein or chemical entity the synthesis of
which is directed by a Gene or Gene pathway, which protein or chemical entity was produced by an organism. 
 1.12
“Food & Beverage Field” means the employment of Enzymes into all the manufacturing and processing of food and beverages and their raw materials and intermediates for human consumption, including baking, beverages, brewing
and malting, fruit and vegetable processing, starch processing, potable alcohol and wine production, protein and fat processing, dairy production and the manufacturing of dietary supplements, in each case for human consumption. 

1.13 “FTE” shall mean the equivalent of one full year of work on a full time basis by a scientist or other
professional (whether an employee or independent contractor of Verenium) possessing skills and experience necessary to carry out the research activities to be conducted by Verenium as contemplated by this Agreement, determined in accordance with
Verenium’s normal policies and procedures. 
 1.14 “Gene” means a polynucleotide sequence that can
be transcribed into RNA and generally encodes a protein, optionally together with its regulatory sequences. 
 1.15
“Grain Ethanol Field” means the employment of Enzymes into the manufacturing of fuel ethanol from any starch or grain. 
 1.16 “Indemnitee” shall have the meaning set forth in Section 9.3. 
 1.17 “Indemnitor” shall have the meaning set forth in Section 9.3. 
 1.18 “Intellectual Property” shall mean all (a) Patent Rights, (b) trademarks, service marks, domain names, trade dress, logos, trade names, and corporate names and
registrations and applications for registration thereof, (c) copyrights and registrations and applications for registration thereof, (d) computer software, data, and documentation, (e) know-how, trade secrets, inventions, data,
processes, procedures, devices, methods, formulas, media, lines, reagents, compounds, protocols and marketing and other proprietary business information, whether or not patentable, (f) other proprietary rights directed to any of the foregoing,
and (g) copies and tangible embodiments of any of the foregoing. 
 1.19 “Joint IP Agreement” shall
have the meaning set forth in Section 3.4. 
 1.20 “Licensed Product” means Veretase or any
Xylanase Product. 

  
 3. 

 1.21 “Licensee New Gene Library Invention” shall have the meaning
set forth in Section 4.6(a). 
 1.22 “Licensee Non-Assert Patent Rights” shall have the meaning set
forth in Section 4.6(b). 
 1.23 “Losses” shall have the meaning set forth in Section 9.1.

 1.24 “NDA” means the Confidentiality, Non-Disclosure and Non-Solicitation Agreement between the
Parties, dated February 8, 2012, as amended by the first Amendment thereto dated February 23, 2012, and the Second Amendment thereto dated March 2, 2012. 
 1.25 “Net Sales” shall mean the gross invoice price of (i) Products sold by Licensee or any of its Affiliates, licensees or sublicensees or (ii) Purchased Enzymes sold by
Verenium or any of its Affiliates, licensees or sublicensees, as applicable, less the following deductions from such gross amounts which are actually incurred and included in gross amounts invoiced: 

(a) price reductions, credits and allowances actually granted in the sale of such Product or Purchased Enzymes, as applicable,
provided no financial or other in-kind contributions (or promise thereof) are received by Licensee or any of its Affiliates or licensees or by Verenium or any of its Affiliates, licensees or sublicensees, as applicable, as compensation for such
adjustments; 
 (b) freight, postage, shipping, customs, duties and insurance charges; and 

(c) sales, value added, or similar taxes measured by the invoiced amount, when included in the invoice. 

Net Sales shall not include sales of Products between Licensee and its Affiliates, licensees and sublicensees; provided, however, that if
Licensee and/or any such Affiliate, licensee or sub-licensee is the end-user of the Product, then Net Sales shall include sales of the Product to Licensee or such Affiliate, licensee or sublicensee, and the sales price hereunder shall be deemed to
be the greater of the price actually charged to Licensee or such Affiliate, licensee or sublicensee, or the sales price that would be charged to a Third Party for a similar application, resale or use in an arms’ length transaction. For
clarification, sales by Verenium to Licensee of Licensed Products under the Supply and Purchase Agreement between Verenium and Licensee, of even date herewith, shall not be included in Net Sales. 

Net Sales shall not include sales of Purchased Enzymes between Verenium and its Affiliates, licensees and sublicensees; provided,
however, that if Verenium and/or any such Affiliate, licensee or sublicensee is the end-user of the Purchased Enzymes, then Net Sales shall include sales of the Purchased Enzymes to Verenium or such Affiliate, licensee or sublicensee, and the sales
price hereunder shall be deemed to be the greater of the price actually charged to Verenium or such Affiliate, licensee or sublicensee, or the sales price that would be charged to a Third Party for a similar application, resale or use in an
arms’ length transaction. 

  
 4. 

 1.26 “New Gene Library” means any library of nucleic acid extracts
and optionally nucleic acids cloned into vectors derived or manufactured from samples of diverse biological materials, which library is created and delivered in the course of New Gene Library Research. 

1.27 “New Gene Library Research” means research conducted by Verenium as described in Section 4.1 during the
New Gene Library Research Period. 
 1.28 “New Gene Library Research Period” means the [...***...]
period immediately following the Effective Date. 
 1.29 “New Product” means any product or
composition containing, incorporating or comprised of any form of an Enzyme identified, discovered, developed or produced by Licensee or any of its Affiliates from or through use of any New Gene Library or any variant of such Enzyme, including,
without limitation, any product that is a blend of such Enzyme and any other Enzyme or product. 
 1.30 “New
Products Field” means any and all fields of use. 
 1.31 “Oil & Gas Field” means the
employment of Enzymes into the exploration and production process and services for mineral oil and natural gas. 
 1.32
“Oil Seed Processing Field” means the employment of Enzymes in the crushing, production, refining, modification and processing of vegetable oil seeds, including but not limited to ricebran, olives, grain, almonds, corn, kernels, soy
beans, canola and sunflower seeds, into their oils, proteins and other components as well as the processing and refining of these components. 
 1.33 “Patent Rights” means all patent applications and issued and subsisting patents, including all provisionals, converted provisionals, requests for continued examination,
substitutions, divisionals, continuations, continuations-in-part, reissues, reexaminations, extensions, supplementary protection certificates, confirmations, registrations, revalidations, revisions, and additions of or to any of the foregoing in any
territory. 
 1.34 “Product” means any Licensed Product or any New Product. 

1.35 “Purchased Enzyme” means any Enzyme claimed or covered by any Purchased IP and any product or composition
containing, incorporating or comprised of any form of such Enzyme (including any product that is a blend of such Enzyme and any other Enzyme or product), including [...***...], but excluding Purchased Products. 

1.36 “Purchased IP” shall mean (a) any and all Intellectual Property included in the Purchased Assets, and
(b) any and all in-licensed Intellectual Property under any contract or agreement included in the Purchased Assets to the extent a sublicense may be granted thereunder, in each case of (a) and (b) together with any and all
Intellectual Property arising from prosecution or maintenance of such Intellectual Property. The Patent Rights included in the Purchased IP as of the Effective Date are set forth in Schedule 1.36. 

  

***Confidential Treatment Requested 

  
 5. 

 1.37 “Purchased Product” means the following
products: (a) the proprietary and patented form of phospholipase C enzyme marketed under the trade name
Purifine® PLC, having the amino acid sequence [...***...] of U.S. Patent Number 7,977,080; (b) the
proprietary and patented form of an [...***...], identified as [...***...]; (c) the proprietary and patented form of an [...***...]; and (d) the [...***...]; and (e) the [...***...]. 

1.38 “Receiving Party” means the Party that receives or observes Confidential Information of the other Party.

 1.39 “Regulatory Authority” means any national, regional, state or local regulatory agency,
department, bureau, commission, council or other governmental entity whose review and/or approval is necessary for the manufacture, packaging, use, storage, import, export, distribution, promotion, marketing, offer for sale and sale of a Product.

 1.40 “[...***...]” means any Enzyme set forth in Schedule 1.40 and any
product or composition containing, incorporating or comprised of any form of such Enzyme (including any product that is a blend of such Enzyme and any other Enzyme or product). 

1.41 “Requesting Party” shall have the meaning set forth in Section 5.8(a). 

1.42 “Syngenta Field” means (a) the manufacture or use of Enzymes and (b) the development, manufacture,
use, sale, offer for sale, import or export of any products that consist of, incorporate or are made through the use of Enzymes, in either case of (a) or (b), which Enzymes are expressed or produced in Plants or using any Gene that is native to
a Plant or modified for expression in Plants, where “Plant” means a monocotyledonous or dicotyledonous plant, or an angiosperm, a gymnosperm or a pteridophyte. 

1.43 “Term” shall have the meaning set forth in Section 10.1. 

1.44 “Third Party” means any person or entity other than Licensee and its Affiliates or Verenium and its
Affiliates. 
 1.45 “Third Party Claims” shall have the meaning set forth in Section 9.1.

 1.46 “Verenium Expression Technology Agreements” means the following agreements pursuant to which
certain expression technology used in the manufacture of certain Purchased Products and Veretase, as well as other products of Verenium, is licensed to Verenium: [...***...]. 

1.47 “Verenium Field” means all fields of use, excluding the Oil Seed Processing Field. For clarification, the
Verenium Field includes the BP Field. 
 1.48 “Verenium Licensed IP” means the Veretase Background IP,
Veretase Licensed IP, Xylanase Products Background IP and Xylanase Products Licensed IP. 
 1.49 “Verenium New
Gene Library Invention” shall have the meaning set forth in Section 4.6(b). 

  

***Confidential Treatment Requested 

  
 6. 

 1.50 “Verenium Non-Assert Patent Rights” shall have the meaning set
forth in Section 4.6(a). 
 1.51 “Verenium Non-Compete” shall have the meaning set forth in
Section 2.2(b). 
 1.52 “Verenium Reserved IP” means any and all Intellectual Property relating to
Verenium’s discovery and evolution technology. 
 1.53 “Verenium-to-BP License Agreement” shall
have the meaning set forth in Section 2.2(a). 
 1.54 “Veretase” means the
proprietary and patented form of alpha-amylase enzyme marketed under the trade name Veretase® alpha-amylase,
having the amino acid sequence [...***...] of U.S. Patent Number 7,666,633, which is approved for use in the hydrolysis of edible starch to produce starch hydrolysis products, including glucose syrup, high fructose corn syrup (HFCS) and
crystalline glucose (dextrose), and distilled ethanol for food and beverage use, and any codon-optimized variant of such enzyme that preserves the same protein sequence as such enzyme. 

1.55 “Veretase Background IP” means Patent Rights Controlled by Verenium, which Patent Rights are useful for the
manufacture, use, marketing, distribution, offer for sale, sale or import of Veretase in the Veretase Field – Exclusive or Veretase Field – Non-Exclusive, but are not included in the Veretase Licensed IP, together with any and all Patent
Rights arising from prosecution or maintenance of such Patent Rights. The Veretase Background IP as of the Effective Date is set forth in Schedule 1.55 (which schedule may be corrected if needed as contemplated by Section 12.9).
Veretase Background IP excludes Verenium Reserved IP. Veretase Background IP also excludes any and all Intellectual Property licensed to Verenium under the Verenium Expression Technology Agreement. 

1.56 “Veretase Customers” means those current customers of Verenium who purchase Veretase for use in the Veretase
Field – Exclusive, as specifically set forth on Schedule 1.56. 
 1.57 “Veretase
Field—Exclusive” means any use of Veretase in the Food & Beverage Field, but excluding the Veretase Reserved Field. 
 1.58 “Veretase Field – Non-Exclusive” means any use of Veretase, excluding all uses in the Food & Beverage Field, the Grain Ethanol Field, [...***...] the
Oil & Gas Field and the BP Field. 
 1.59 “Veretase Licensed IP” means any and all Intellectual
Property Controlled by Verenium, which Intellectual Property is necessary for the manufacture, use, marketing, distribution, offer for sale, sale or import of Veretase in the Veretase Field – Exclusive or Veretase Field – Non-Exclusive,
together with any and all Intellectual Property arising from prosecution or maintenance of such Intellectual Property. The Patent Rights included in the Veretase Licensed IP as of the Effective Date are set forth in Schedule 1.59.
Veretase Licensed IP excludes Verenium Reserved IP. Veretase Licensed IP also excludes any and all Intellectual Property licensed to Verenium under the Verenium Expression Technology Agreement. 

  

***Confidential Treatment Requested 

  
 7. 

 1.60 “Veretase Reserved Field” means [...***...]. 

1.61 “Xylanase Products” means (a) the proprietary and patented form of xylanase enzyme, having the amino
acid sequence [...***...] of U.S. Patent Number 8,043,839, and any codon-optimized variant of such enzyme that preserves the same protein sequence as such enzyme, and (b) the proprietary and patented form of xylanase enzyme, having the
amino acid sequence [...***...] of U.S. Patent Number 8,043,839, and any codon-optimized variant of such enzyme that preserves the same protein sequence as such enzyme. 
 1.62 “Xylanase Products Background IP” means Patent Rights Controlled by Verenium, which Patent Rights are useful for the manufacture, use, marketing, distribution, offer for sale,
sale or import of Xylanase Products in the Xylanase Products Field, but are not included in the Xylanase Products Licensed IP, together with any and all Patent Rights arising from prosecution or maintenance of such Patent Rights. The Xylanase
Products Background IP as of the Effective Date is set forth in Schedule 1.62 (which schedule may be corrected if needed as contemplated by Section 12.9). Xylanase Products Background IP excludes Verenium Reserved IP. Xylanase
Products Background IP also excludes any and all Intellectual Property licensed to Verenium under the Verenium Expression Technology Agreement. 
 1.63 “Xylanase Products Field” means any use of a Xylanase Product in the Oil Seed Processing Field and the Food & Beverage Field, excluding all uses in the
[...***...] and the Syngenta Field. 
 1.64 “Xylanase Products Licensed IP” means any and all
Intellectual Property Controlled by Verenium, which Intellectual Property is necessary for the manufacture, use, marketing, distribution, offer for sale, sale or import of any Xylanase Product in the Xylanase Products Field, together with any and
all Intellectual Property arising from prosecution or maintenance of such Intellectual Property. Xylanase Products Licensed IP excludes Verenium Reserved IP. The Patent Rights included in the Xylanase Products Licensed IP as of the Effective Date
are set forth in Schedule 1.64. Xylanase Products Licensed IP excludes any and all Intellectual Property licensed to Verenium under the Verenium Expression Technology Agreement. 

ARTICLE 2 

RIGHTS TO PURCHASED IP 

2.1 License Grant to Verenium under Purchased IP. Subject to the terms and conditions of this Agreement, Licensee hereby
grants to Verenium and its Affiliates (a) an exclusive, worldwide, royalty bearing (except that no royalty shall be due as provided under Section 2.2(a) and 5.2) right and license or sublicense, with the right to sublicense, under and with
respect to the Purchased IP to make, have made, use, develop, market, distribute, offer for sale, sell and import Purchased Enzymes in the Verenium Field, and (b) a non-exclusive, worldwide, royalty-free and fully paid, perpetual and
irrevocable right and license or sublicense, with the right to sublicense, under and with respect to the Purchased IP to make, have made, use, develop, market, distribute, offer for sale, sell and import Purchased Products in the BP Field. Verenium
shall have the right under the license granted in this Section 2.1 to make variants of 

  

***Confidential Treatment Requested 

  
 8. 

 
any Purchased Enzyme (as defined in Sections 1.35) that have [...***...], and all such variants shall be deemed included in and part of Purchased Enzymes. Promptly after the Effective
Date, Licensee shall disclose to Verenium in writing or via mutually acceptable electronic media (or allow Verenium to retain) copies or reproductions of data, know-how and information included in the Purchased IP that is reasonably necessary to
enable Verenium to practice the licenses granted under this Section 2.1 in the Verenium Field, it being understood that such data, know-how and information may not be all data, know-how and information necessary for the development, manufacture
and commercialization of Purchased Enzymes in the Verenium Field. From and after the Effective Date, Verenium shall refrain from using the trademark Purifine in the Verenium Field. 

2.2 Provisions Applicable to Purchased IP. Verenium and Licensee hereby acknowledges and agrees as follows: 

(a) License Granted to BP in the BP Field. Verenium has granted to BP and its affiliates a non-exclusive, worldwide,
royalty-free and fully paid, perpetual and irrevocable right and license, with the right to sublicense, under and with respect to the Purchased IP, for products and services in the BP Field as set forth in that certain Verenium License Agreement
between Verenium and BP, dated as of September 2, 2010, as amended (the “Verenium-to-BP License Agreement”). Licensee acknowledges and agrees that the Purchased IP is subject to such license granted to BP and that the license
granted to Verenium in Section 2.1 includes all rights necessary to enable such license granted to BP to remain in full force and effect in accordance with its terms. Licensee further agrees to comply with all of Verenium’s obligations to
BP relating to the Purchased IP under the Verenium-to-BP License Agreement as if it were a party to such agreement. 

(b) Verenium Non-Compete. Verenium has agreed to the Verenium Non-Compete (as defined below). Licensee agrees not to,
itself or through any Affiliate, licensee or other Third Party, practice or use the Purchased IP in a manner that would violate the Verenium Non-Compete were Verenium to practice or use the Purchased IP in such manner. The “Verenium
Non-Compete” means Verenium’s agreement pursuant to the Verenium Non-Competition Agreement between Verenium and BP, dated as of September 2, 2010, as amended that Verenium and its Affiliates shall not, anywhere in the world,
engage, directly or indirectly, individually or in association or in combination with any other person, as proprietor or owner, officer, director or shareholder (other than as a passive investor in and holder of less than 5% of the equity of any
publicly traded corporation), member or manager of any limited liability company, or as an employee, agent, independent contractor, consultant, advisor, joint venturer, trustee, licensee, sublicensee, licensor, sublicensor, principal, partner or
otherwise, whether or not for monetary benefit, in: 
 (i) any business that researches, develops, manufactures,
produces, distributes, licenses or sells biofuels or bioproducts derived from lignocellulosic biomass (which for the avoidance of doubt excludes starch to ethanol, starch to other biofuels and starch to bioproducts) for a period ending
September 2, 2012; 

  

***Confidential Treatment Requested 

  
 9. 

 (ii) directly or indirectly, with any third party, the researching, development,
manufacture, production, licensing, sublicensing or sale of any Processes, for a period ending September 2, 2017; where “Processes” means any process or partial process for conversion or partial conversion of biomass to
lignocellulosic biofuels and/or lignocellulosic bioproducts; provided that “process” and “partial process” shall not mean or include any enzymes or enzyme technology (including technology or equipment for manufacture, delivery or
optimization of the enzyme application), or the application thereof, that may be used in or as part of any such process or partial process; 
 (iii) directly or indirectly, any business that researches, develops, manufactures, produces, licenses, sublicenses or sells any Processes, for a period ending September 2, 2017; 

provided that, notwithstanding the foregoing, Verenium and its Affiliates shall have the right to: (A) research, develop, manufacture, produce,
license and sell enzymes and enzyme technology within the markets of the activities in the BP Field carried on or conducted by BP or any of its affiliates; and/or (B) integrate Verenium’s and its Affiliates’ enzymes and enzyme
technology with any third party’s lignocellulosic biofuels production process that does not produce ethanol primarily from lignocellulosic biomass, but instead uses feedstocks of waste products or byproducts arising solely from completed
industrial manufacturing processes. For purposes of this clause (B), completed industrial manufacturing processes means, and is limited to, the completed manufacturing processes in the industries of grain processing, oil seed processing, pulp and
paper, distilleries, breweries, and any other additional industries that BP provides written consent to and expressly excludes any completed industrial manufacturing processes related to sugar cane or energy cane. 

(c) Biodiversity Agreement Payments. If Verenium owes any payment under any biodiversity or similar agreement as a result
of any sale, license or other transfer by Licensee or any of its Affiliates or licensees of any Purchased Product or Purchased Enzyme and/or the use of any of the Purchased IP, Verenium will invoice Licensee for the amount of such payment, and
Licensee shall pay the invoice within thirty (30) days after the receipt of the invoice. Licensee will provide Verenium summary reports of efforts by Licensee or any of its Affiliates or licensees to develop and commercialize any Purchased
Product or Purchased Enzyme, which reports shall be provided at least once per year, to Verenium to determine whether there are any obligations under any biodiversity agreement. 

2.3 Label License. All Purchased Enzyme sales by Verenium and its Affiliates, licensees and sublicensees will be subject to
an appropriate label license that limits use of Purchased Enzymes to the Verenium Field. 
 2.4 Limitations.
Except as provided in this Article 2, Licensee shall retain all of its rights under the Purchased IP. Licensee agrees, on behalf of itself and its Affiliates, not to practice or use, and not to grant any license or right to practice or use,
the Purchased IP to make, have made, use, develop, market, distribute, offer for sale, sell or import Purchased Enzymes in the Verenium Field. Verenium agrees, on behalf of itself and its Affiliates, not to practice any Purchased IP except as
expressly provided in this Article 2. 

  
 10.

 2.5 Sublicenses. Verenium shall notify Licensee promptly after the grant of
any sublicense of the license granted under this Section 2.1 to any Third Party, and the terms of any such sublicense shall be consistent with the terms of this Agreement applicable to the Purchased IP and Purchased Enzymes. 

ARTICLE 3 

RIGHTS TO VERENIUM LICENSED IP 

3.1 License Grant to Licensee under Veretase Background IP and Veretase Licensed IP. Subject to the terms and conditions of
this Agreement and subject to the Supply and Purchase Agreement between Verenium and Licensee, dated as of even date herewith, with respect to supply of Veretase, Verenium hereby grants to Licensee and its Affiliates (a) an exclusive,
worldwide, royalty-bearing right and license, with the right to sublicense, under and with respect to the Veretase Licensed IP to make, have made, use, develop, market, distribute, offer for sale, sell and import Veretase in the Veretase Field
– Exclusive, (b) a non-exclusive, worldwide, royalty-bearing right and license, with the right to sublicense, under and with respect to the Veretase Background IP to make, have made, use, develop, market, distribute, offer for sale, sell
and import Veretase in the Veretase Field – Exclusive, and (c) a non-exclusive, worldwide, royalty-bearing right and license, with the right to sublicense, under and with respect to the Veretase Background IP and the Veretase Licensed IP
to make, have made, use, develop, market, distribute, offer for sale, sell and import Veretase in the Veretase Field – Non-Exclusive. Licensee shall have the right under the license granted in this Section 3.1 to make variants of Veretase
(as defined in Section 1.54) that have [...***...], and all such variants shall be deemed included in and part of Veretase. Promptly after the Effective Date, Verenium shall disclose to Licensee in writing or via mutually acceptable
electronic media copies or reproductions of data, know-how and information included in the Veretase Licensed IP that is reasonably necessary to enable Licensee to practice the license granted under this Section 3.1 in the Veretase Field –
Exclusive and Veretase Field—Non-Exclusive, it being understood that such data, know-how and information may not be all data, know-how and information necessary for the development, manufacture and commercialization of Veretase in the Veretase
Field – Exclusive and Veretase Field—Non-Exclusive. 
 3.2 Acknowledgement Regarding Veretase. Licensee
acknowledges that Verenium has licensed rights to Veretase in the Veretase Reserved Field and is obligated to ensure that Veretase is sold only pursuant to a limited label license that allows use of Veretase only for uses outside the Veretase
Reserved Field. For so long as Verenium is subject to such obligation, Licensee agrees, on behalf of itself, its Affiliates, licensees and sublicensees, that, when it supplies or grants rights to Veretase to any Third Party, it will do so only
pursuant to a limited label license that allows such Third Party to use Veretase only for uses outside the Veretase Reserved Field, such limited label license to be in the form used by Verenium and provided to Licensee. In the event that Licensee
discovers that a Third Party to whom Licensee or its Affiliate, licensee or sublicensee has supplied or granted rights to Veretase is using Veretase within the Veretase Reserved Field, Licensee shall immediately notify Verenium, and Licensee

  

***Confidential Treatment Requested 

  
 11.

 
agrees to use commercially reasonable efforts, consistent with efforts Licensee would use to protect its exclusive right to operate for its own products, to procure such Third Party to cease such
activity forthwith, which efforts may include, at Licensee’s sole discretion, terminating or limiting any additional supply of Veretase to such Third Party and issuing proceedings against the Third Party to enforce the terms of the label
license. 
 3.3 License Grant to Licensee under Xylanase Products Background IP and Xylanase Products Licensed IP.
Subject to the terms and conditions of this Agreement, Verenium hereby grants, to Licensee and its Affiliates an exclusive, worldwide, royalty-bearing right and license, with the right to sublicense, under and with respect to the Xylanase Products
Background IP and the Xylanase Products Licensed IP to make, have made, use, develop, market, distribute, offer for sale, sell and import Xylanase Products in the Xylanase Products Field. Licensee shall have the right under the license granted in
this Section 3.3 to make variants of any Xylanase Product (as defined in Section 1.61) that have [...***...], and all such variants shall be deemed included in and part of Xylanase Products. Promptly after the Effective Date,
Verenium shall disclose to Licensee in writing or via mutually acceptable electronic media copies or reproductions of data, know-how and information included in the Xylanase Products Licensed IP that is reasonably necessary to enable Licensee to
practice the license granted under this Section 3.3 in the Xylanase Products Field, it being understood that such data, know-how and information may not be all data, know-how and information necessary for the development, manufacture and
commercialization of Xylanase Products in the Xylanase Products Field. 
 3.4 Acknowledgement Regarding Xylanase
Products. Licensee acknowledges and agrees that the Xylanase Products Background IP and the Xylanase Products Licensed IP is subject to the terms of the Joint Intellectual Property Agreement between Verenium and BP, dated as of September 2,
2010, as amended (the “Joint IP Agreement”). Under the Joint IP Agreement, under certain circumstances Verenium is obligated to assign the Xylanase Products Background IP and the Xylanase Products Licensed IP to BP, and effective
automatically upon such assignment, Verenium shall have a non-exclusive, worldwide right and license under the Xylanase Products Background IP and the Xylanase Products Licensed IP for all uses for products and services outside the BP Field and the
Syngenta Field. Under such circumstances, the license granted in Section 3.3 shall be an exclusive license of Verenium’s rights under the non-exclusive license granted to it with respect to the Xylanase Products Background IP the Xylanase
Products Licensed IP under the Joint IP Agreement. Licensee acknowledges and agrees that the license granted in Section 3.3 is subject to the terms and conditions of the Joint IP Agreement. 

3.5 Label License. All Veretase sales by Licensee and its Affiliates, licensees and sublicensees will be subject to an
appropriate label license that limits use of Veretase to the Veretase Field – Exclusive and Veretase Field – Non-Exclusive and meets the requirements set forth in Section 3.2, which label license shall be in substantially the form
provided by Verenium to Licensee. All Xylanase Product sales by Licensee and its Affiliates, licensees and sublicensees will be subject to an appropriate label license that limits use of Xylanase Products to the Xylanase Products Field, which label
license shall be in substantially the form provided by Verenium to Licensee. 

  

***Confidential Treatment Requested 

  
 12.

 3.6 Biodiversity Agreement Payments. If Verenium owes any payment under any
biodiversity agreement as a result of any sale, license or other transfer by Licensee or any of its Affiliates, licensees or sublicensees to a Third Party of any Licensed Product, Verenium will invoice Licensee for the amount of such payment, and
Licensee shall pay the invoice within thirty (30) days after the receipt of the invoice. 
 3.7 Retained Rights;
Limitation. Except as provided in this Article 3, Verenium (or its licensor) shall retain all rights under the Verenium Licensed IP. Licensee, on behalf of itself and its Affiliates, agrees not to practice any Verenium Licensed IP except as
expressly provided in this Article 3 and agrees not to make any variants of any Licensed Product except as expressly provided in this Article 3 or the applicable definition of Licensed Product. 

3.8 Sublicenses. Licensee shall notify Verenium promptly after the grant of any sublicense of the license granted under
Section 3.1 or 3.3 to any Third Party, and the terms of any such sublicense shall be consistent with the terms of this Agreement applicable to Verenium Licensed IP and Licensed Products. 

3.9 Verenium Agreement. Verenium agrees not to sell or market, alone or with or through a license to any of its Affiliates
or any Third Party, [...***...] unless agreed in writing by Verenium and Licensee. Subject to Verenium’s contractual obligations and restrictions, and Verenium and Licensee entering into a Materials Transfer Agreement substantially in the
form as attached hereto as Schedule 3.9, Verenium will agree to make [...***...] available for testing by Licensee upon first request of Licensee. Verenium reserves all rights with respect to [...***...] except as expressly
provided in this Section 3.9, including the right to sell and market, alone or with or through a license to any of its Affiliates or any Third Party, [...***...]. 
 3.10 Certain Customers; Distribution Agreements. Following the Effective Date, the Parties shall work together in good faith to transition the Veretase Customers to Licensee for the
continued sale of Veretase by Licensee for use by such Veretase Customers in the Veretase Field – Exclusive. The Parties understand and agree that there are no written contracts or agreements covering the supply of Veretase to such Veretase
Customers. Verenium currently has certain distribution arrangements with Weiss Biotech, Anthem and [...***...] related to such entities’ distribution and sale of Veretase. The Parties acknowledge and agree that Licensee is not, either
under this Agreement or the Asset Purchase Agreement or any of the other ancillary agreements to the Asset Purchase Agreement, receiving an assignment of any of the distribution agreements that are in effect with such distributors. Verenium shall,
however, provide such reasonable assistance to Licensee as Licensee may reasonably request during the 90 day period following the Effective Date to facilitate Licensee’s efforts, if any, to establish direct relationships between Licensee and
such distributors of Veretase, including, if requested, providing introductions to Verenium’s contact persons at such distributors. 
 ARTICLE 4 
 NEW GENE LIBRARY
RESEARCH; RIGHTS TO NEW GENE LIBRARIES 
 4.1 Conduct of New Gene Library Research. Subject to the terms and conditions of this Agreement, during the New Gene Library Research Period, Verenium will use Intellectual

  

***Confidential Treatment Requested 

  
 13.

 
Property Controlled by it to conduct a research program for creation of nucleic acid extracts and optionally nucleic acids cloned into vectors derived or manufactured from samples of diverse
biological materials obtained pursuant to Verenium’s biodiversity agreements as currently in effect. Verenium will deploy [...***...] FTEs in the New Gene Library Research and use commercially reasonable efforts to create
[...***...] New Gene Libraries during each [...***...] period (or such longer number of days as reasonably necessary to obtain the necessary permits in connection with Verenium’s relocation to a new site) over the New Gene Library
Research Period. Verenium will conduct the New Gene Library Research at its own expense. 
 4.2 Delivery of New Gene
Libraries. Promptly after creation a New Gene Library, Verenium shall deliver to Licensee a copy of such New Gene Library. 

4.3 Right to Use New Gene Libraries; Limitation on Transfer. 

(a) Right to Use New Gene Libraries. Licensee and its Affiliates shall have the non-exclusive, non-transferable, worldwide
right to access and use the copy of the New Gene Libraries provided by Verenium for the purpose of identifying, discovering, developing and producing Enzymes from the New Gene Libraries, without limit as to field. 

(b) Limitation on Transfer. Licensee and its Affiliates shall not copy the New Gene Libraries other than for preservation
or repeat studies (and any such copies are included in and part of the New Gene Libraries), and shall not transfer or assign the New Gene Libraries, except as expressly set forth in Section 12.3 hereof. Further, Licensee shall not transfer any
physical embodiment of any of the New Gene Libraries to any Third Party, except with the prior written consent of Verenium; provided that, to the extent the New Gene Libraries contain an isolated clone of a Gene or its DNA sequence, a subclone
thereof, or a purified Enzyme produced therefrom, Licensee and its Affiliates may transfer to any particular Third Party (including the Affiliates of such Third Party) up to 100 unique samples (such samples to be comprised of clones or DNA
sequences, subclones and/or enzymes totaling 100 in the aggregate) without the prior written consent of Verenium, subject to a written agreement with such Third Party that includes confidentiality and non-use obligations consistent with the terms of
this Agreement. 
 4.4 Biodiversity Agreement Payments. If Verenium owes any payment under any biodiversity or
similar agreement as a result of any sale, license or other transfer by Licensee or any of its Affiliates or licensees of any New Product, Verenium will invoice Licensee for the amount of such payment, and Licensee shall pay the invoice within
thirty (30) days after the receipt of the invoice. Licensee will provide Verenium summary reports of efforts by Licensee or any of its Affiliates or licensees to develop and commercialize any New Product, which reports shall be provided at
least once per year, to Verenium to determine whether there are any obligations under any biodiversity agreement. 
 4.5
Retained Rights; Limitation. Verenium shall retain all rights to use the New Gene Libraries for any purpose. Licensee, on behalf of itself and its Affiliates, agrees not to use the New Gene Libraries except as expressly provided in this
Article 4. 

  

***Confidential Treatment Requested 

  
 14.

 4.6 Non-Assert Agreements. 

(a) Verenium Non-Assert. In the event that the manufacture, development or commercialization of any Enzyme identified,
discovered, developed or produced by Licensee or any of its Affiliates from or through use of any New Gene Library or any variant of such Enzyme, or any product or composition containing, incorporating or comprised of any form of any such Enzyme (a
“Licensee New Gene Library Invention”), would infringe any Patent Rights filed by Verenium or any of its Affiliates after the Effective Date claiming any Verenium New Gene Library Invention (“Verenium Non-Assert Patent
Rights”), then Verenium hereby covenants to Licensee that Verenium and its Affiliates will not, and Verenium will cause any party that acquires rights to any Verenium Non-Assert Patent Rights from Verenium or its Affiliate, not to, assert
or enforce such Verenium Non-Assert Patent Rights against Licensee or its Affiliate or any licensee of any Licensee New Gene Library Invention solely with respect to Licensee’s or its Affiliate’s or such licensee’s manufacture,
development or commercialization of such Licensee New Gene Library Invention. 
 (b) Licensee Non-Assert. In the
event that the manufacture, development or commercialization of Enzyme identified, discovered, developed or produced by Verenium or any of its Affiliates from or through use of any New Gene Library or any variant of such Enzyme, or any product or
composition containing, incorporating or comprised of any form of any such Enzyme (a “Verenium New Gene Library Invention”), would infringe any Patent Rights filed by Licensee or any of its Affiliates after the Effective Date
claiming any Licensee New Gene Library Invention (“Licensee Non-Assert Patent Rights”), then Licensee hereby covenants to Verenium that Licensee and its Affiliates will not, and Licensee will cause any party that acquires rights to
any Licensee Non-Assert Patent Rights from Licensee or its Affiliate, not to, assert or enforce such Licensee Non-Assert Patent Rights against Verenium or its Affiliate or any licensee of any Verenium New Gene Library Invention solely with respect
to Verenium’s or its Affiliate’s or such licensee’s manufacture, development or commercialization of such Verenium New Gene Library Invention. 
 4.7 Additional Research. Verenium and Licensee may agree to an additional research program whereby Verenium would screen Licensee’s libraries and/or Verenium’s proprietary Gene
libraries for Genes of interest to Licensee [...***...]. Any such additional research program would be conducted on terms to be mutually agreed in writing by the Parties. 
 ARTICLE 5 
 PAYMENTS; RECORDS;
AUDITS 
 5.1 Payment of Royalties by Licensee on Licensed Products and New Products. Subject
to the terms and conditions of this Agreement, in consideration for the licenses and rights granted to Licensee under this Agreement, Licensee shall pay to Verenium royalties of [...***...] on Net Sales of Products. On a country-by-country
basis and Product-by-Product basis, Licensee’s obligation to make royalty payments pursuant to this Section 5.1 will commence upon the first commercial sale of any Product in any country and shall continue until

  

***Confidential Treatment Requested 

  
 15.

 
the later of (a) expiration of the last-to-expire Patent Rights within the Verenium Licensed IP that covers the composition of such Product, or the manufacture or use of such Product in the
field with respect to which such Product is licensed under this Agreement, in such country, and (b) [...***...] after the first commercial sale of such Product in such country. No more than one royalty payment shall be due with respect to
a sale of a particular Licensed Product or New Product. 
 5.2 Payment of Royalties by Verenium on Purchased
Enzymes. Subject to the terms and conditions of this Agreement, in consideration for the licenses and rights granted to Verenium under this Agreement, Verenium shall pay to Licensee royalties of [...***...] on Net Sales of Purchased
Enzymes. On a country-by-country basis and Purchased Enzyme-by-Purchased Enzyme basis, Verenium’s obligation to make royalty payments pursuant to this Section 5.2 will commence upon the first commercial sale of any Purchased Enzyme in any
country and shall continue until the earlier of (a) expiration of the last-to-expire Patent Rights within the Purchased IP that covers the composition of such Purchased Enzyme, or the manufacture or use of such Purchased Enzyme in the Verenium
Field, in such country, and (b) [...***...] after the first commercial sale of such Purchased Enzyme in such country. Notwithstanding anything to the contrary herein, in no event will any royalty be due or payable hereunder on sales of
any product or service by BP pursuant to the Verenium-to-BP License Agreement. No more than one royalty payment shall be due with respect to a sale of a particular Purchased Enzyme. 

5.3 Fully Paid License to Licensee. With respect to Veretase, on a country-by-country basis, upon the later to occur of
(a) expiration of the last-to-expire of all Patent Rights within the Veretase Background IP and the Veretase Licensed IP in such country, or (b) the date that there are no remaining royalty payment obligations with respect to Veretase in
such country pursuant to Section 5.1, the license granted to Licensee under Section 3.1 in such country shall become perpetual, non-exclusive, fully paid-up, royalty free license. With respect to Xylanase Products, on a country-by-country
and Xylanase Product-by-Xylanase Product basis, upon the later to occur of (i) expiration of the last-to-expire of all Patent Rights within the Xylanase Products Background IP and the Xylanase Products Licensed IP that covers the composition of
such Xylanase Product, or the manufacture or use of such Xylanase Product in the Xylanase Products Field in such country, or (ii) the date that there are no remaining royalty payment obligations with respect to such Xylanase Product in such
country pursuant to Section 5.1, the license granted to Licensee under Section 3.1 with respect to such Xylanase Product in such country shall become perpetual, non-exclusive, fully paid-up, royalty free license. 

5.4 Fully Paid License to Verenium. On a country-by-country basis and Purchased Enzyme-by-Purchased Enzyme basis, upon the
later to occur of (a) expiration of the last-to-expire of all Patent Rights within the Purchased IP that covers the composition of such Purchased Enzyme, or the manufacture or use of such Purchased Enzyme in the Verenium Field in such country,
or (b) the date that there are no remaining royalty payment obligations with respect to such Purchased Enzyme in such country pursuant to Section 5.2, the licenses granted to Verenium under Section 2.1 with respect to such Purchased
Enzyme in such country shall become perpetual, non-exclusive, fully paid-up, royalty free license. 

  

***Confidential Treatment Requested 

  
 16.

 5.5 Payment to Designated Account. All payments due under this Agreement shall
be payable in United States dollars. Each Party shall make all payments to the other Party by bank wire transfer in immediately available funds to an account designated in writing by the Party to whom such payment is due. 

5.6 Conversion. All amounts payable under this Section will first be calculated in the currency of sale and then converted
into United States dollars. The buying rates involved for the currency of the United States into which the currencies involved are being exchanged shall be the arithmetic averages of the ones quoted by the Eastern Edition of The Wall Street Journal
at the close of business on the last business day of each calendar month of the applicable quarter. In the event that such publication no longer publishes such rates, another financial publication mutually agreed on by the Parties shall substitute
the previous one or one shall be chosen by an investment banker/analyst mutually agreed on by the Parties. 
 5.7
Books and Records. Each Party agrees to keep (and cause its applicable Affiliates to keep) proper records and books of account in accordance with Accounting Standards, showing the Net Sales upon which the calculation of royalties are based,
and all other information necessary for the accurate determination of payments to be made in accordance with this Agreement. Such records shall be maintained for at least three years after the date of the applicable payment to which such records
relates. 
 5.8 Audit. 
 (a) Audit Procedures and Timing. Upon the written request of Licensee (with respect to sales of Purchased Enzymes by Verenium or its Affiliates, licensees or sublicensees) or Verenium (with
respect to sales of Products by Licensee or its Affiliates, licensees or sublicensees) (as applicable, the “Requesting Party”), and not more than once in each calendar year, the other Party (the “Audited Party”)
shall permit an independent certified public accounting firm of nationally recognized standing selected by the Audited Party and reasonably acceptable to the Requesting Party to have access during normal business hours to such of the records of the
Audited Party and its applicable Affiliates as may be reasonably necessary to verify the accuracy of the payments due and costs incurred under this Agreement, including the reports of Net Sales under this Agreement, for any period ending not more
than three years prior to the date of such request. The accounting firm shall disclose to the Requesting Party only whether the payments due and costs incurred, including any payment reports (as applicable), are correct or incorrect and the specific
details concerning any discrepancies. No other information shall be provided to the Requesting Party without the prior consent of the Audited Party unless disclosure is required by law, regulation or judicial order. The Audited Party is entitled to
require the accounting firm to execute a reasonable confidentiality agreement prior to commencing any such audit. 
 (b)
Payments. The fees charged by such accounting firm shall be paid by the Requesting Party; provided, however, that if the audit uncovers an underpayment by the Audited Party that exceeds 5% of the total payment owed, then the fees of such
accounting firm shall be paid by the Audited Party unless the reason for such underpayment was a miscalculation on the part of the Audited Party. Any underpayments or unpaid amounts discovered by such audit or otherwise will be paid promptly by the
Audited Party within 30 days of the date the Audited 

  
 17.

 
Party delivers to the Requesting Party such accounting firm’s written report, or as otherwise agreed upon by the Parties, plus interest calculated in accordance with Section 5.10 unless
the reason for such underpayment was a miscalculation on the part of the Audited Party. In the event of an overpayment by the Audited Party, the Audited Party shall be entitled to credit such overpayment against any subsequent payment due to the
Requesting Party under this Agreement. 
 5.9 Taxes. A Party receiving payment under this Agreement shall pay any
and all income or franchise taxes levied on account of royalties and other payments it receives hereunder. If laws or regulations require that taxes be withheld, the paying Party will deduct such taxes from the amount due to the Party to whom such
payment is due, pay such taxes to the proper tax authority, and send evidence of the obligation together with proof of payment to the Party to whom such payment is due promptly after making such payment. 

5.10 Late Payments. Payments not remitted or deposited by the due date shall bear interest to the extent permitted by
applicable law at the then-current prime rate plus 2% established by CitiBank, as published in The Wall Street Journal, calculated on the number of days such payment is delinquent. The payment of such interest shall not limit the Party entitled to
receive such payment from exercising any other rights it may have as a consequence of the lateness of any payment. 
 ARTICLE
6 
 INTELLECTUAL PROPERTY RIGHTS 

6.1 Filing, Prosecution, and Maintenance of Patent Rights. 

(a) Verenium. Verenium (or its licensor with respect to any Patent Rights licensed to Verenium by a Third Party) shall be
responsible, in its sole discretion and at its sole expense, for filing, prosecuting, maintaining, defending and enforcing any Patent Rights within the Verenium Licensed IP. Verenium will keep Licensee reasonably informed with regard to the filing,
prosecution and maintenance of the Patent Rights within the Verenium Licensed IP. In addition, with regard to Patent Rights within the Verenium Licensed IP that are subject to any exclusive license granted to Licensee hereunder, Verenium will
consult with Licensee as to material decisions of Verenium regarding the filing, prosecution and maintenance of such Patent Rights reasonably prior to any deadline or action. In the event that Verenium determines not to file for any Patent Rights
within the Verenium Licensed IP that are subject to any exclusive license granted to Licensee hereunder or to abandon or cease prosecution or maintenance of any such Patent Rights, Verenium shall provide reasonable prior written notice to Licensee
of such intention not to file or to abandon or cease prosecution or maintenance. In such case, subject to the rights of Verenium’s licensor with respect to any Patent Rights licensed to Verenium by a Third Party or its licensees under Patent
Rights licensed by Verenium to a Third Party, Licensee may elect, upon written notice by Licensee to Verenium, to cause Verenium to file such Patent Rights or to continue prosecution and/or maintenance of such Patent Rights, at Licensee’s sole
cost and expense and in accordance with Licensee’s instructions, and Verenium shall do so for as long as Licensee continues to pay the costs and expenses of filing for, prosecuting and/or maintaining such Patent Rights. Licensee shall reimburse
Verenium for such costs and expenses incurred by Verenium within 30 days from the date of invoice for such costs and expenses by 

  
 18.

 
Verenium, and Licensee may credit the amount of such costs and expenses reimbursed by Licensee against royalties payable to Verenium under Article 5. In the event that Licensee desires to
cease bearing the costs and expenses with respect to any such Patent Rights, Licensee shall provide prior written notice to Verenium of such intention. In such case, Verenium, at its sole discretion, may elect to continue preparing, filing,
prosecuting and maintaining any such Patent Rights at its own expense. 
 (b) Licensee. Licensee (or its licensor
with respect to any Patent Rights licensed to Licensee by a Third Party) shall be responsible, in its sole discretion and at its sole expense, for filing, prosecuting, maintaining, defending and enforcing any Patent Rights within the Purchased IP.
Licensee will keep Verenium reasonably informed with regard to the filing, prosecution and maintenance of the Patent Rights within the Purchased IP. In addition, with regard to Patent Rights within the Purchased IP that are subject to any exclusive
license granted to Verenium hereunder, Licensee will consult with Verenium as to material decisions of Licensee regarding the filing, prosecution and maintenance of such Patent Rights reasonably prior to any deadline or action. In the event that
Licensee determines not to file for any Patent Rights within the Purchased IP that are subject to any exclusive license granted to Verenium hereunder or to abandon or cease prosecution or maintenance of any such Patent Rights, Licensee shall provide
reasonable prior written notice to Verenium of such intention not to file or to abandon or cease prosecution or maintenance. In such case, subject to the rights of Licensee’s licensor with respect to any Patent Rights licensed to Licensee by a
Third Party or its licensee sunder Patent Rights licensed by Licensee to a Third Party, Verenium may elect, upon written notice by Verenium to Licensee, to cause Licensee to file such Patent Rights or to continue prosecution and/or maintenance of
such Patent Rights, at Verenium’s sole cost and expense and in accordance with Verenium’s instructions, and Licensee shall do so for as long as Verenium continues to pay the costs and expenses of filing for, prosecuting and/or maintaining
such Patent Rights. Verenium shall reimburse Licensee for such costs and expenses incurred by Licensee within 30 days from the date of invoice for such costs and expenses by Licensee. In the event that Verenium desires to cease bearing the costs and
expenses with respect to any such Patent Rights, Verenium shall provide prior written notice to Licensee of such intention. In such case, Licensee, at its sole discretion, may elect to continue preparing, filing, prosecuting and maintaining any such
Patent Rights at its own expense. 
 6.2 Infringement by Third Parties. 

(a) Notice. In the event that either Verenium or Licensee becomes aware of any infringement or threatened infringement by a
Third Party of any Patent Rights that are subject to prosecution, maintenance or enforcement by the other Party under this Agreement, it will notify the other Party in writing. Any such notice shall include evidence to support an allegation of
infringement or threatened infringement by such Third Party. 
 (b) Verenium Rights. Verenium (or its Third Party
licensor with respect to any Patent Rights licensed to Verenium by such Third Party) shall have the sole right (but not the obligation), as between Verenium and Licensee, to bring and control any action or proceeding with respect to infringement of
any Patent Rights within the Verenium Licensed IP, at its own expense and by counsel of its own choice. Verenium will notify Licensee of any such action brought by Verenium. During any time that Licensee holds an exclusive license under the Patent

  
 19.

 
Rights within the Veretase Licensed IP in the Veretase Field—Exclusive, Licensee shall have the right, at its own expense, to be represented in any such action brought by Verenium with
respect to infringement of any such Patent Rights in the Veretase Field—Exclusive by counsel of its own choice, and Verenium and its counsel will reasonably cooperate with Licensee and its counsel in strategizing, preparing and presenting any
such action or proceeding. 
 (c) Licensee Rights. Licensee (or its Third Party licensor with respect to any
Patent Rights licensed to Licensee by such Third Party) shall have the sole right (but not the obligation), as between Verenium and Licensee, to bring and control any action or proceeding with respect to infringement of any Patent Rights within the
Purchased IP, at its own expense and by counsel of its own choice. Licensee will notify Verenium of any such action brought by Licensee. During any time that Verenium holds an exclusive license under the Patent Rights within the Purchased IP in the
Verenium Field, Verenium shall have the right, at its own expense, to be represented in any such action brought by Licensee with respect to infringement of any such Patent Rights in the Verenium Field by counsel of its own choice, and Licensee and
its counsel will reasonably cooperate with Verenium and its counsel in strategizing, preparing and presenting any such action or proceeding. 
 (d) Cooperation; Awards. In the event a Party brings an infringement action in accordance with this Section 6.2, the other Party shall cooperate fully as appropriate. Any recovery or
damages realized as a result of such action or proceeding shall be used first to reimburse the Parties’ documented out-of-pocket legal expenses relating to the action or proceeding, and any remaining recovery or damages shall be retained by the
Party that brought or controlled the action or proceeding and, to the extent such recovery or damages relates to Products (including, without limitation, lost sales or lost profits with respect to Products) shall be deemed Net Sales and subject to
the payment of royalties in accordance with Article 5. 
 6.3 Infringement of Third Party Rights. Verenium
and Licensee shall promptly notify the other in writing of any allegation by a Third Party that the exercise of the rights granted to the other Party hereunder infringes or may infringe the Intellectual Property of such Third Party. Licensee shall
have the sole right to control any defense of any such claim involving alleged infringement of a Third Party’s Intellectual Property by Licensee’s or its Affiliate’s, licensee’s or sublicensee’s activities (other than any
activities by Verenium or its licensees or sublicensees) at Licensee’s own expense and by counsel of its own choice, and Verenium shall have the right, at its own expense, to be represented in any such action by counsel of its own choice.
Verenium shall have the sole right to control any defense of any such claim involving alleged infringement of a Third Party’s Intellectual Property by Verenium’s or its Affiliate’s, licensee’s or sublicensee’s activities
(other than any activities by Licensee or its licensees or sublicensees) at Verenium’s own expense and by counsel of its own choice, and Licensee shall have the right, at its own expense, to be represented in any such action by counsel of its
own choice. Neither Party shall have the right to settle any patent infringement litigation under this Section 6.3 in a manner that diminishes the rights of the other Party under this Agreement without the prior written consent of such other
Party. 

  
 20.

 ARTICLE 7 
 CONFIDENTIALITY 
 7.1 Confidentiality
Obligations. The Receiving Party agrees that, subject to disclosures permitted or contemplated by this Agreement, it shall: 

(a) Maintain all Confidential Information in strict confidence, except that the Receiving Party may disclose or permit the
disclosure of any Confidential Information to its or its Affiliates’ contractors, consultants, agents, advisors, directors, officers and employees who are obligated to maintain the confidential nature of such Confidential Information subject to
a confidentiality obligation no less restrictive in scope than the confidentiality obligations of the Parties hereunder and who need to know such Confidential Information for the purposes set forth in this Agreement; 

(b) Use all Confidential Information solely for the purposes set forth in, or as permitted by, this Agreement or any other written
agreement between the Parties; and 
 (c) Allow its or its Affiliates’ contractors, consultants, agents, advisors,
directors, officers and employees who are subject to a confidentiality obligation no less restrictive in scope than the confidentiality obligations of the Parties hereunder to reproduce the Confidential Information only to the extent necessary to
effect the purposes set forth in this Agreement, with all such reproductions being considered Confidential Information. 
 Each Party shall be
responsible for any breaches of this Section 7.1 by any of its or its Affiliates’ contractors, consultants, agents, advisors, directors, officers and employees. 
 7.2 Exceptions. The obligations of the Receiving Party under Section 7.1 above shall not apply to any specific Confidential Information to the extent that the Receiving Party can
demonstrate by competent proof that such Confidential Information: 
 (a) Was generally known to the public or otherwise
part of the public domain prior to the time of its disclosure under this Agreement; 
 (b) Entered the public domain
after the time of its disclosure under this Agreement through means other than an unauthorized disclosure resulting from an act or omission by the Receiving Party’s or its Affiliates’, contractors, consultants, agents, advisors, directors,
officers or employees; 
 (c) Was already known to the Receiving Party, other than under an obligation of
confidentiality, at the time of disclosure by the Disclosing Party; 
 (d) Is or was disclosed to the Receiving Party at
any time, whether prior to or after the time of its disclosure under this Agreement, by a Third Party having no fiduciary relationship with the Disclosing Party and having no obligation of confidentiality to the Disclosing Party with respect to such
Confidential Information; or 
 (e) Is developed by the Receiving Party without use of any Confidential Information of
the Disclosing Party. 

  
 21.

 7.3 Permitted Disclosure. Each Party shall be permitted to disclose
Confidential Information in the event that, and only to the extent that, such information is required to be disclosed to comply with applicable laws or regulations (such as disclosure to the United States Securities and Exchange Commission or the
United States Environmental Protection Agency) or the rules of any stock exchange upon which a Party’s securities are listed, or to comply with a court or administrative order, provided that the Disclosing Party receives prior written notice of
such disclosure and that the Receiving Party takes all reasonable and lawful actions to obtain confidential treatment for such disclosure and, if possible, to minimize the extent of such disclosure. In addition, each Party may disclose the terms of
this Agreement to lenders, investment bankers, financial institutions or other Third Parties (including licensees or sublicensees) solely for purposes of due diligence investigations or financing the business operations of such Party or granting
licenses or sublicenses as contemplated by this Agreement, either (a) upon the written consent of the other Party or (b) if the disclosing Party obtains a signed confidentiality agreement with such Third Party with respect to such
information, upon terms consistent with those set forth in this Article 7. 
 7.4 Public Announcements.
Except for the information disclosed in any press release made in connection with the closing of the transactions contemplated by the Asset Purchase Agreement, neither Party shall use the name of the other Party or reveal the existence of or terms
of this Agreement in any publicity or advertising without the prior written approval of the other Party, except that (a) either Party may use the text of a written statement approved in advance by both Parties without further approval, and
(b) either Party shall have the right to identify the other Party and to disclose the terms of this Agreement as provided in Section 7.3 or as required by the rules of the Securities and Exchange Commission or any similar regulatory
authority in any jurisdiction outside the United States. The Parties shall coordinate in advance with each other in connection with the filing of this Agreement (including redaction of certain provisions of this Agreement) with the Securities and
Exchange Commission or any similar regulatory authority in any jurisdiction outside the United States, and each Party shall use reasonable efforts to seek confidential treatment for the terms proposed to be redacted; provided, that each Party shall
ultimately retain control over what information to disclose to Securities and Exchange Commission or any similar regulatory authority in any jurisdiction outside the United States. 

7.5 Equitable Relief. Given the nature of the Confidential Information and the competitive damage that would result to a
Party upon unauthorized disclosure, use or transfer of its Confidential Information to any Third Party, the Parties agree that monetary relief would not may be a sufficient remedy for any breach of this Article 7. In addition to all other
remedies, a Party shall be entitled to specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this Article 7. 

  
 22.

 ARTICLE 8 
 REPRESENTATIONS; WARRANTIES; COVENANT; DISCLAIMERS 
 8.1 Organization; Good Standing. Each Party hereby represents to the other Party on the Effective Date that it: 
 (a) is a corporation duly organized, validly existing, 
 (b) is in
good standing under the laws of the jurisdiction of its incorporation, 
 (c) is qualified to do business and in good
standing in each jurisdiction in which the performance of its obligations hereunder requires such qualification, and 

(d) has all requisite power and authority, corporate or otherwise, and the legal right to conduct its business as now being
conducted, to execute, deliver and perform its obligations under this Agreement. 
 8.2 Binding Obligation; Due
Authorization; No Conflict; Verenium Representation. Each Party hereby represents to the other Party on the Effective Date that this Agreement is a legal and valid obligation binding upon its execution and enforceable in accordance with its
terms and conditions. The execution, delivery, and performance of this Agreement by such Party have been duly authorized by all necessary corporate action, and the person executing this Agreement on behalf of such Party has been duly authorized to
do so by all requisite corporate actions and do not and will not (a) conflict with, or constitute a material breach or violation of, any agreement, instrument, understanding, oral or written, to which it is a party or by which it may be bound,
and any judgment of any court or governmental body applicable to such a Party, or (b) violate any law, decree, order, rule or regulation of any court, governmental body or administrative or other agency having authority over it. Verenium
represents to Licensee on the Effective Date that no Third Party has brought or threatened in writing to bring any action or proceeding against Verenium alleging that the sale of any of the Purchased Products or Licensed Products that are marketed
and sold by Verenium as of the Effective Date infringe any issued patent owned by such Third Party. 
 8.3
Covenant. The Parties agree to use reasonable efforts to (a) obtain consent from the licensor under the applicable Verenium Expression Technology Agreement as needed to permit Verenium to sublicense the Intellectual Property licensed
under such the Verenium Expression Technology Agreements to Licensee for use in the manufacture of the Purchased Products, Purchased Enzymes and/or Licensed Products, as applicable, or (b) facilitate License obtaining a license directly from
the licensor under the applicable Verenium Expression Technology Agreement for such purpose. 

  
 23.

 8.4 Disclaimers. Each Party hereby acknowledges that the data and any
materials provided or licensed hereunder are of an experimental nature, provided without warranties, and neither Party shall accept any liability in connection with their use, storage and disposal by the other Party. EXCEPT AS EXPRESSLY SET FORTH IN
THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY TO THE OTHER PARTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF NON-INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. WITHOUT LIMITING THE GENERALITY
OF THE FOREGOING, EACH PARTY ACKNOWLEDGES THAT NO WARRANTY IS MADE REGARDING THE UTILITY OF ANY INFORMATION, MATERIALS OR TECHNOLOGY LICENSED HEREUNDER. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, EACH PARTY EXPRESSLY DISCLAIMS ALL WARRANTIES
AS TO THE VALIDITY OR SCOPE OF PATENTS AND PATENT CLAIMS, ISSUED AND PENDING, PROTECTING ITS TECHNOLOGY OR THAT ANY TECHNOLOGY WILL BE FREE FROM INFRINGEMENT OF PATENTS OR PROPRIETARY RIGHTS OF THIRD PARTIES, OR THAT NO THIRD PARTIES ARE IN ANY WAY
INFRINGING PATENT RIGHTS. 
 ARTICLE 9 
 INDEMNIFICATION 
 9.1 By Licensee. Licensee
shall indemnify, defend, and hold harmless Verenium and its Affiliates and their directors, officers, employees and agents and their respective successors, heirs and assigns, against any and all losses, liabilities, damages, penalties, fines, costs
and expenses (including reasonable attorneys’ fees and other expenses of litigation) (“Losses”) incurred by any such indemnified party as a result of any claims, actions, suits or proceedings brought by a Third Party (a
“Third Party Claims”) arising from or relating to [...***...] any material breach of any representations, warranties or covenants by Licensee under this Agreement; except to the extent such Losses are directly
attributable to the negligence or willful misconduct of a party seeking indemnification under this Section 9.1. 

9.2 By Verenium. Verenium shall indemnify, defend, and hold harmless Licensee and its Affiliates and their directors,
officers, employees and agents and their respective successors, heirs and assigns, against any and all Losses incurred by any such indemnified party as a result of any Third Party Claims arising from or relating to [...***...] any
material breach of any representations, warranties or covenants by Verenium under this Agreement; except to the extent such Losses are directly attributable to the negligence or willful misconduct of a party seeking indemnification under this
Section 9.2. 
 9.3 Procedures. Any party that intends to claim indemnification under Section 9.1 or
9.2, as the case may be (an “Indemnitee”), shall promptly notify either Verenium or Licensee, as applicable (the “Indemnitor”), of any Third Party Claim in respect of which the Indemnitee intends to claim such
indemnification, and the Indemnitor shall assume the defense thereof with counsel mutually satisfactory to the Parties; provided, however, that an Indemnitee shall have the right to retain its own counsel at its own expense. Section 9.1 or 9.2,
as the case may be, shall not apply to amounts paid in settlement of any loss, claim, liability or action if such settlement is effected without the consent of the Indemnitor. Without prejudice to the provision contained in

  

***Confidential Treatment Requested 

  
 24.

 
the previous sentence, the failure to deliver notice to the Indemnitor within a reasonable time after the commencement of any such action shall not relieve the Indemnitor of any liability to the
Indemnitee under Section 9.1 or 9.2, as the case may be, except to the extent the Indemnitor has been prejudiced by such failure to give notice. Each Party and its Affiliates and their employees and agents shall cooperate fully with the other
Party and its legal representatives in the investigation of any action, claim or liability covered by this Article 9. 

9.4 Insurance. Each Party agrees to maintain a liability insurance program which is consistent with sound business practice
and reasonable in light of its obligations under this Agreement. 
 ARTICLE 10 

TERM; TERMINATION 
 10.1 Term. The term of is Agreement shall commence as of the Effective Date and, unless earlier terminated as provided herein, shall continue in effect until the later to occur of
(i) expiration of the last-to-expire of all Patent Rights within the Verenium Licensed IP and the Purchased IP, or (ii) the date that there are no remaining royalty payment obligations in any country pursuant to Sections 5.1 and 5.2
(the “Term”). 
 10.2 Mutual Consent. This Agreement may be terminated or extended at any time by
mutual written agreement of the Parties. 
 10.3 Material Breach. 

(a) Notice of Breach. In the event of any breach or default of any material representation, warranty or obligation under
this Agreement by a Party, the non-breaching Party shall give the breaching Party written notice thereof, which notice must state the nature of the breach or default in reasonable detail and request that the breaching Party cure such breach or
default. 
 (b) Termination for Breach. Except for disputes as to payment (which disputes are dealt with under
Section 10.3(c)), the non-breaching Party may, in addition to any other remedies which may be available to such non-breaching Party at law or equity, terminate this Agreement in the event of a material breach or default that has not been cured
within 60 days after receipt of notice of such breach or default. 
 (c) Breach of Payment Obligations. In the
event that a Party fails to make timely payment of any amounts that are not the subject of a good faith dispute regarding payment and that are due under this Agreement within 30 days after demand therefor, the other Party may terminate this
Agreement upon 30 days prior written notice, unless such Party cures such breach by paying all past-due amounts that are not the subject of a good-faith dispute between the Parties within such 30-day notice period. 

10.4 Termination for Patent Challenges. Licensee shall have the right to terminate this Agreement immediately upon written
notice to Verenium if Verenium or any of its Affiliates directly, or indirectly through any Third Party, commences any interference or opposition 

  
 25.

 
proceeding with respect to, challenges the validity or enforceability of, or opposes any extension of or the grant of a supplementary protection certificate with respect to, any Patent Rights
within the Purchased IP. Verenium shall have the right to terminate this Agreement immediately upon written notice to Licensee if Licensee or any of its Affiliates directly, or indirectly through any Third Party, commences any interference or
opposition proceeding with respect to, challenges the validity or enforceability of, or opposes any extension of or the grant of a supplementary protection certificate with respect to, any Patent Rights within the Verenium Licensed IP. 

10.5 Bankruptcy. 
 (a) Termination. A Party may terminate this Agreement if, during the Term, the other Party shall file in court or agency pursuant to any statute or regulation of any state or country, a
petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of the Party or of its assets, or if the other Party proposes a written agreement of composition or extension of its
debts, or if the other Party shall be served with an involuntary petition in bankruptcy or seeking reorganization, liquidation, dissolution, winding-up arrangement, composition or readjustment of its debts or any other relief under any bankruptcy,
insolvency, reorganization or other similar act or law of any jurisdiction now or hereafter in effect, or there shall have been issued a warrant of attachment, execution or similar process against it, filed in any insolvency proceeding, and such
petition shall not be dismissed within 90 days after the filing thereof, or if the other Party shall propose or be a Party to any dissolution or liquidation, or if the other Party shall make an assignment for the benefit of creditors. 

(b) Rights in Bankruptcy. All rights and licenses granted under or pursuant to this Agreement are, and shall otherwise be
deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code or comparable provisions under any bankruptcy, insolvency, reorganization or other similar act or law applicable to a Party, licenses of rights to “intellectual
property” as defined under Section 101 of the U.S. Bankruptcy Code or comparable provisions under any bankruptcy, insolvency, reorganization or other similar act or law applicable to a Party. The Parties agree that each Party that is a
licensee of such rights under this Agreement shall retain and may fully exercise its rights and elections under the U.S. Bankruptcy Code or comparable provisions under any bankruptcy, insolvency, reorganization or other similar act or law applicable
to a Party. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against either Party under the U.S. Bankruptcy Code or comparable provisions under any bankruptcy, insolvency, reorganization or other
similar act or law applicable to a Party, the Party hereto which is not a Party to such proceeding shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such
intellectual property, and same, if not already in their possession, shall be, within 10 days of the commencement of such proceeding, delivered to them (i) upon any such commencement of a bankruptcy proceeding upon their written request
therefore, unless the Party subject to such proceeding (or a trustee on behalf of the subject Party) elects to continue to perform all of their obligations under this Agreement or (ii) if not delivered under (i) above, upon the rejection
of this Agreement by or on behalf of the Party subject to such proceeding upon written request therefore by the non-subject Party. 

  
 26.

 10.6 Disposition of Confidential Information. In the event of termination or
expiration of this Agreement, except to the extent that a Party retains a license from the other Party under this Agreement following such termination or expiration, the Parties shall return or destroy all Confidential Information of the other Party
within 30 days after such termination or expiration, provided, however, that each Party may retain one copy of such Confidential Information for record keeping purposes subject to a continuing obligation of confidentiality under Article 7.

 10.7 Effect of Termination or Expiration. Upon termination or expiration of this Agreement, all rights and
obligations of the Parties under this Agreement shall terminate except as provided in this Section 10.7. Termination or expiration of this Agreement shall not relieve the Parties of any obligation accruing prior to such termination or
expiration. The provisions of Articles 1, 2, 7, 9, 11 and 12 and Sections 4.3, 4.4, 4.5, 4.6, 5.5, 5.6, 8.4, 10.6 and 10.7 shall survive the expiration or termination of this Agreement. In addition, (a) any license granted under
Section 3.1 or 3.3 that became perpetual and irrevocable pursuant to Section 5.3 prior to expiration or termination of this Agreement (together with the terms of Article 3 applicable to such license) shall survive such expiration or
termination. Termination of this Agreement shall not limit any rights and remedies of the Parties, and (b) any licenses granted under Section 2.1 that became perpetual and irrevocable pursuant to Section 5.4 prior to expiration or
termination of this Agreement (together with the terms of Article 2 applicable to such license) shall survive such expiration or termination. Termination of this Agreement shall not limit any rights and remedies of the Parties. If this
Agreement is terminated by Verenium pursuant to Section 10.3, 10.4 or 10.5, any sublicensee of rights under the licenses granted pursuant to Section 3.1 or 3.3 shall, from the effective date of such termination, automatically become a
direct licensee of Verenium with respect to the rights licensed under Section 3.1 or 3.3 and sublicensed to such sublicensee by Licensee; provided that such sublicensee is not in breach of its sublicense and such sublicensee agrees to comply
with all of the terms of this Agreement to the extent applicable to the rights sublicensed to it by Licensee. If this Agreement is terminated by Licensee pursuant to Section 10.3, 10.4 or 10.5, any sublicensee of rights under the licenses
granted pursuant to Section 2.1 shall, from the effective date of such termination, automatically become a direct licensee of Licensee with respect to the rights licensed under Section 2.1 and sublicensed to such sublicensee by Verenium;
provided that such sublicensee is not in breach of its sublicense and such sublicensee agrees to comply with all of the terms of this Agreement to the extent applicable to the rights sublicensed to it by Verenium. 

ARTICLE 11 

DISPUTE RESOLUTION 
 11.1 Disputes. If any dispute arising out of or relating to this Agreement remains unresolved for 30 days after one Party has delivered written notice describing such dispute to the other
Party, either Party may refer such dispute to the Chief Executive Officer of Licensee and the Chief Executive Officer of Verenium, who shall meet in person or by telephone within 30 days after such referral to attempt in good faith to resolve such
dispute. If such matter cannot be resolved by discussion of such officers within such 30-day period (as may be extended by mutual written agreement), such dispute shall, be resolved in accordance with Section 11.2. 

  
 27.

 11.2 Jurisdiction. To the fullest extent permitted by applicable law, each
Party hereto (a) agrees that any claim, action or proceeding by such party seeking any relief whatsoever arising out of, or in connection with, this Agreement or the transactions contemplated hereby shall be brought only in the courts of the
State of New York and not in any other State or Federal court in the United States of America or any court in any other country, (b) agrees to submit to the exclusive jurisdiction of the courts of the State of New York for purposes of all legal
proceedings arising out of, or in connection with, this Agreement or the transactions contemplated hereby, (c) waives and agrees not to assert any objection that it may now or hereafter have to the laying of the venue of any such proceeding
brought in such a court or any claim that any such proceeding brought in such a court has been brought in an inconvenient forum, (d) agrees that mailing of process or other papers in connection with any such action or proceeding in the manner
provided in Section 12.4 or any other manner as may be permitted by law shall be valid and sufficient service thereof and (e) agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other
jurisdictions by suit on the judgment or in any other manner provided by applicable law. 
 11.3 Waiver of Jury Trial.
EACH PARTY HERETO WAIVES THE RIGHT TO A TRIAL BY JURY IN ANY DISPUTE ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, OR ANY MATTERS DESCRIBED OR CONTEMPLATED HEREIN. 
 ARTICLE 12 
 MISCELLANEOUS 

12.1 Force Majeure. Neither Party shall be held liable or responsible to the other Party nor be deemed to have defaulted
under or breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement (other than non-payment) when such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party,
including fire, floods, earthquakes, natural disasters, embargoes, war, acts of war (whether war be declared or not), insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, acts of God or acts, omissions or delays in
acting by any governmental authority. 
 12.2 Third Parties. Nothing in this Agreement, express or implied, is
intended to confer upon any party, other than the Parties hereto and their respective successors and permitted assigns, any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as otherwise provided in this
Agreement with respect to Indemnitees under Article 9. 
 12.3 Assignment. This Agreement may not be assigned
or otherwise transferred, nor may any right or obligations hereunder be assigned or transferred, by either Party to any Third Party without the prior written consent of the other Party; except that either Party may assign or otherwise transfer this
Agreement without the consent of the other Party to an entity that acquires all or substantially all of the business or assets of the assigning Party relating to the subject matter of the licenses granted by and/or granted to the assigning Party
under this Agreement, whether by merger, acquisition or otherwise, provided that Intellectual Property that is owned or held by the acquiring entity (if other than one of the Parties to this Agreement) shall not be included in the Intellectual
Property subject to this Agreement. Upon assignment, the rights and obligations under this Agreement shall be binding upon and inure to the benefit of said purchaser or successor in interest. Any assignment of this Agreement in contravention of this
Section 12.3 shall be null and void. 

  
 28.

 12.4 Notices. All notices, requests, demands and other communications required
or permitted to be given pursuant to this Agreement shall be in writing and shall be deemed to have been duly given upon the date of receipt if delivered by hand, overnight courier or confirmed facsimile or electronic mail (email) transmission to
the following addresses or facsimile numbers: 
  

			
		
	 If to Licensee:
	  	If to Verenium:
		
	 DSM Food Specialties B.V.
	  	Verenium Corporation
	 Alexander Fleminglaan 1

2613 AX Delft
 Netherlands
	  	 4955 Directors Place
 San
Diego, California 92121
 United States of America

	 Attention: Business Group Director
	  	Attention: Chief Executive Officer
	
Tel:                 
                   
 Fax: +31152792796
	  	 Tel: (858) 431-8504
 Fax:
(858) 876-9496

	 E-mail: Hans-christian.ambjerg@dsm.com
	  	E-mail: james.levine@verenium.com
		
	 with a copy to:
	  	with a copy to:
		
	 DSM NA
	  	Verenium Corporation
	 45 Waterview Blvd.
	  	4955 Directors Place
	 Parsippany NJ 07054

United States of America
	  	 San Diego, California 92121

United States of America

	 Attention: President & General Counsel
	  	Attention: General Counsel
	 Tel: (973)         -        
	  	Tel: (858) 431-8508
	 Fax: (973) 257-8208
	  	Fax: (858) 876-9496
	 E-mail: hugh.welsh@dsm.com
	  	E-mail: alexander.fitzpatrick@verenium.com

 Either Party may change its designated address, facsimile number, or e-mail address by notice to the other Party in the
manner provided in this Section 12.4. 
 12.5 Governing Law. This Agreement shall be governed by and
construed and enforced in accordance with the internal laws of the State of New York without giving effect to the principles of conflicts of law thereof. The United Nations Conventions on Contracts for the International Sale of Goods shall not be
applicable to this Agreement. 
 12.6 Amendment and Waiver. This Agreement may be amended, supplemented, or
otherwise modified only by means of a written instrument signed by both Parties. Any waiver of any rights or failure to act in a specific instance shall relate only to such instance and shall not be construed as an agreement to waive any rights or
fail to act in any other instance, whether or not similar. 

  
 29.

 12.7 Severability. In the event that any provision of this Agreement shall,
for any reason, be held to be invalid or unenforceable in any respect, such invalidity or unenforceability shall not affect any other provision hereof, and the Parties shall negotiate in good faith to modify the Agreement to preserve (to the extent
possible) their original intent. 
 12.8 Relationship of Parties. It is expressly agreed that Verenium and
Licensee shall be independent contractors and that nothing in this Agreement is intended or shall be deemed to constitute a partnership, agency, distributorship, employer-employee or joint venture relationship between the Parties. No Party shall
incur any debts or make any commitments for the other, except to the extent, if at all, specifically provided herein. 

12.9 Entire Agreement. This Agreement and the schedules and exhibits hereto constitute the entire agreement between the
Parties with respect to the subject matter hereof and supersede all prior and contemporaneous agreements, representations, and understandings of the Parties with respect to the subject matter hereof, including the NDA. If, after the Effective Date,
the Parties become aware that any schedule attached to this Agreement is not complete or correct, the Parties will work together to correct such schedule as appropriate. No Party hereto shall be liable or bound to the other in any manner by any
warranties, representations or covenants with respect to the subject matter hereof except as specifically set forth herein. 

12.10 Headings. The captions contained in this Agreement are not a part of this Agreement, but are merely guides or labels
to assist in locating and reading the several Articles hereof. 
 12.11 Counterparts. This Agreement may be
executed via facsimile and in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument, and shall become effective when there exist copies hereof which, when taken
together, bear the authorized signatures of each of the Parties hereto. Only one such counterpart signed by the Party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement. 

12.12 Exports. The Parties acknowledge that the export of technical data, materials or products is subject to the exporting
Party receiving any necessary export licenses and that the Parties cannot be responsible for any delays attributable to export controls which are beyond the reasonable control of either Party. Verenium and Licensee agree not to export or re-export,
directly or indirectly, any information, technical data, the direct product of such data, samples, products or equipment received or generated under this Agreement in violation of any applicable export control laws or governmental regulations.

 12.13 Language. The Parties hereto confirm their agreement that this Agreement, as well as any amendment hereto
and all other documents related hereto, including legal notices, have been and shall be in the English language only. 

12.14 No Implied Licenses. No right or license under any Intellectual Property of Verenium or Licensee is granted or shall
be granted by implication, but shall be granted only as expressly provided in the terms of this Agreement. 

  
 30.

 12.15 Limitation of Liability for Indirect Damages. EXCEPT FOR AMOUNTS PAYABLE
UNDER ARTICLE 5 OR FOR LIABILITY FOR BREACH OF CONFIDENTIALITY, IN NO EVENT WILL EITHER PARTY, ITS DIRECTORS, OFFICERS, EMPLOYEES, AGENTS OR AFFILIATES BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, CONSEQUENTIAL,
PUNITIVE OR MULTIPLE DAMAGES, OR FOR LOST PROFITS, LOST DATA OR LOSS OF USE DAMAGES, WHETHER BASED UPON A CLAIM OR ACTION OF CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHER TORT, OR OTHERWISE, ARISING OUT OF THIS AGREEMENT. NOTHING IN THIS
SECTION IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS UNDER ARTICLE 9. 
 12.16
Interpretation. All references in this Agreement to an Article, Section or Schedule shall refer to an Article, Section or Schedule in or to this Agreement, unless otherwise stated. Any reference to any federal, national, state, local, or
foreign statute or law shall be deemed also to refer to all rules and regulations promulgated thereunder, unless the context requires otherwise. The word “including” and similar words means including without limitation. The words
“herein,” “hereof” and “hereunder” and other words of similar import refer to this Agreement as a whole and not to any particular Section or other subdivision. All references to days, months, quarters or years are
references to calendar days, calendar months, calendar quarters, or calendar years, unless stated otherwise. References to the singular include the plural. 
 (signature page follows) 

  
 31.

 IN WITNESS WHEREOF, the Parties have executed this
LICENSE AGREEMENT as of the Effective Date set forth above. 
  

							
	VERENIUM CORPORATION:	 		 	DSM FOOD SPECIALTIES B.V.
				
	By: /s/ James
Levine                                        
                    	 		 	By:	 	/s/ Hans Christian Ambjerg
	Name: James Levine	 		 	Name:	 	Hans Christian Ambjerg
	Title: CEO	 		 	Title:	 	Director
				
		 		 	By:	 	/s/ Hugh Welsh
		 		 	Name:	 	Hugh Welsh
		 		 	Title:	 	President DSM NA
		 		 		 	

 SIGNATURE PAGE TO LICENSE
AGREEMENT 

 SCHEDULE 1.36 

Patent Rights Included in Purchased IP 

 SCHEDULE 1.40 

Patent Rights Describing [...***...] 
 Any [...***...]. 

  

***Confidential Treatment Requested 

 SCHEDULE 1.55 

Veretase Background IP 

 SCHEDULE 1.56 

Veretase Customers 

Customers: 
 [...***...]

 Distributors: 
 The
following entities are distributors of Veretase, but also have relationships with the Company in addition to Veretase: 
 Anthem Cellutions
(India) Ltd 
 [...***...] 

WeissBio Tech GmbH 

  

***Confidential Treatment Requested 

 SCHEDULE 1.59 

Patent Rights Included in Veretase Licensed IP 

 SCHEDULE 1.62 

Xylanase Products Background IP 

 SCHEDULE 1.64 

Patent Rights Included in Xylanase Products Licensed IP 

 SCHEDULE 3.9 

Materials Transfer Agreement 

 SCHEDULE 1.36 

Patent Rights Included in Purchased IP 
  

																									
	 SYT
	 	 Family
Name
	 	Type	  	Owner	  	Case
Number	  	Country	  	Application
Status	  	Application
Number	  	Filing
Date	  	Publication
Number	  	Publication
Date	  	Patent
Number	  	Issue
Date
	Y	 	[...***...]	 	Patent	  	Verenium	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	Y	 	[...***...]	 	Patent	  	Verenium	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	Y	 	[...***...]	 	Patent	  	Verenium	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	Y	 	[...***...]	 	Patent	  	Verenium	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	Y	 	[...***...]	 	Patent	  	Verenium	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	Y	 	[...***...]	 	Patent	  	Verenium	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	Y	 	[...***...]	 	Patent	  	Verenium	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	Y	 	[...***...]	 	Patent	  	Verenium	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	Y	 	[...***...]	 	Patent	  	Verenium	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	Y	 	[...***...]	 	Patent	  	Verenium	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	Y	 	[...***...]	 	Patent	  	Verenium	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	Y	 	[...***...]	 	Patent	  	Verenium	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	Y	 	[...***...]	 	Patent	  	Verenium	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	Y	 	[...***...]	 	Patent	  	Verenium	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	Y	 	[...***...]	 	Patent	  	Verenium	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	Y	 	[...***...]	 	Patent	  	Verenium	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	Y	 	[...***...]	 	Patent	  	Verenium	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	Y	 	[...***...]	 	Patent	  	Verenium	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	Y	 	[...***...]	 	Patent	  	Verenium	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	Y	 	[...***...]	 	Patent	  	Verenium	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	Y	 	[...***...]	 	Patent	  	Verenium	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	Y	 	[...***...]	 	Patent	  	Verenium	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	Y	 	[...***...]	 	Patent	  	Verenium	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	Y	 	[...***...]	 	Patent	  	Verenium	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]

  

***Confidential Treatment Requested 

  
 1 

																									
	 SYT
	  	 Family
Name
	 	Type	 	Owner	 	Case
Number	 	Country	 	Application
Status	 	Application
Number	 	Filing
Date	 	Publication
Number	 	Publication
Date	 	Patent
Number	 	Issue
Date
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]

  

***Confidential Treatment Requested 

  
 2 

																									
	 SYT
	  	 Family
Name
	 	Type	 	Owner	 	Case
Number	 	Country	 	Application
Status	 	Application
Number	 	Filing
Date	 	Publication
Number	 	Publication
Date	 	Patent
Number	 	Issue
Date
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Y	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	N	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	N	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	N	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	N	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	N	  	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]

  

***Confidential Treatment Requested 

  
 3 

																									
	 SYT
	 	 Family
Name
	 	Type	 	Owner	 	Case
Number	 	Country	 	Application
Status	 	Application
Number	 	Filing
Date	 	Publication
Number	 	Publication
Date	 	Patent
Number	 	Issue
Date
	N	 	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	N	 	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	N	 	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	N	 	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	N	 	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	N	 	[...***...]	 	Patent	 	Verenium	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	N/A	 	PURIFINE	 	Trademark	 	Verenium	 	T8160-
AR01	 	AR	 	TM-Registd	 	2971646	 	13-Jan-
2010	 	2971646	 	31-Mar-
2010	 	2404628	 	29-Oct-
2010
	N/A	 	PURIFINE	 	Trademark	 	Verenium	 	T8160-
BO01	 	BO	 	Pending	 	SM-4545-
2011	 	25-Aug-
2011	 		 		 		 	
	N/A	 	PURIFINE	 	Trademark	 	Verenium	 	T8160-
BR01	 	BR	 	Pending	 	830520619	 	11-Jan-
2010	 		 		 		 	
	N/A	 	PURIFINE	 	Trademark	 	Verenium	 	T8160-
CA01	 	CA	 	Pending	 	1,465,141	 	08-Jan-
2010	 		 		 		 	
	N/A	 	PURIFINE	 	Trademark	 	Verenium	 	T8160-
CN01	 	CN	 	Pending	 	7997784	 	15-Jan-
2010	 		 		 		 	
	N/A	 	PURIFINE	 	Trademark	 	Verenium	 	T8160-
CTM01	 	EM	 	TM-Registd	 	8799744	 	08-Jan-
2010	 	8799744	 	15-Mar-
2010	 	8799744	 	28-Jun-
2010
	N/A	 	PURIFINE	 	Trademark	 	Verenium	 	T8160-
IN01	 	IN	 	TM-Pending	 	2193919	 	23-Aug-
2011	 		 		 		 	
	N/A	 	PURIFINE	 	Trademark	 	Verenium	 	T8160-
KR01	 	KR	 	TM-Pending	 	40-2011-
45591	 	22-Aug-
2011	 		 		 		 	
	N/A	 	PURIFINE	 	Trademark	 	Verenium	 	T8160-
MX01	 	MX	 	TM-Pending	 	1205328	 	23-Aug-
2011	 		 		 		 	
	N/A	 	PURIFINE	 	Trademark	 	Verenium	 	T8160-
PY01	 	PY	 	TM-Pending	 	35148	 	22-Aug-
2011	 		 		 		 	
	N/A	 	PURIFINE	 	Trademark	 	Verenium	 	T8160-
TH01	 	TH	 	TM-Pending	 	817628	 	24-Aug-
2011	 		 		 		 	
	N/A	 	PURIFINE	 	Trademark	 	Verenium	 	T8160-
US01	 	US	 	TM-Registd	 	78/564,145	 	09-Feb-
2005	 		 		 	3308380	 	09-Oct-
2007
	N/A	 	PURIFINE	 	Trademark	 	Verenium	 	T8160-
UY01	 	UY	 	TM-Pending	 	427457	 	21-Sep-
2011	 		 		 		 	

  

***Confidential Treatment Requested 

  
 4 

																									
	 SYT
	  	 Family
Name
	  	Type	  	Owner	  	Case
Number	  	Country	  	Application
Status	  	Application
Number	  	Filing
Date	  	Publication
Number	  	Publication
Date	  	Patent
Number	  	Issue
Date
	N/A	  	purifine.com	  	Domain	  	Verenium	  		  		  		  		  		  		  		  		  	
	N/A	  	purifine.us	  	Domain	  	Verenium	  		  		  		  		  		  		  		  		  	

  
 5 

 SCHEDULE 1.55 

Veretase Background IP 
  

																	
	 Owner
	 	 Type
	 	Name/Family	 	Docket No.	 	Country	 	Application No.	 	Filing Date	 	Patent/Trademark
No.	 	Issue Date
	[...***...]	 	Patent	 	Amylase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Amylase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Amylase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Amylase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Amylase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Amylase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Amylase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Amylase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Amylase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Amylase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Amylase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Amylase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Amylase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Amylase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Amylase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Amylase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Amylase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Amylase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Amylase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Amylase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Amylase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Amylase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]

  

***Confidential Treatment Requested 

  
 6 

																	
	 Owner
	 	 Type
	 	Name/Family	 	Docket No.	 	Country	 	Application No.	 	Filing Date	 	Patent/Trademark
No.	 	Issue Date
	[...***...]	 	Patent	 	Amylase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Amylase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Amylase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Amylase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Amylase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]

  

***Confidential Treatment Requested 

  
 7 

 SCHEDULE 1.59 

Patent Rights Included in Veretase Licensed IP 
  

															
	 Type
	 	 Owner
	 	Docket No.	 	Country	 	Application No.	 	Filing Date	 	Patent No.	 	Issue Date
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]

  

***Confidential Treatment Requested 

  
 8 

															
	 Type
	 	 Owner
	 	Docket No.	 	Country	 	Application No.	 	Filing Date	 	Patent No.	 	Issue Date
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]

  

***Confidential Treatment Requested 

  
 9 

 SCHEDULE 1.62 

Xylanase Products Background IP 
  

																	
	 Owner
	 	 Type
	 	Name/Family	 	Docket No.	 	Country	 	Application No.	 	Filing Date	 	Patent/Trademark
No.	 	Issue Date
	[...***...]	 	Patent	 	Xylanase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Xylanase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Xylanase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Xylanase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Xylanase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Xylanase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Xylanase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Xylanase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Xylanase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Xylanase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Xylanase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	Patent	 	Xylanase	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]

  

***Confidential Treatment Requested 

  
 10 

 SCHEDULE 1.64 

Patent Rights Included in Xylanase Products Licensed IP 

 

															
	 Type
	 	 Owner
	 	Docket No.	 	Country	 	Application No.	 	Filing Date	 	Patent No.	 	Issue Date
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	Patent	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]

  

***Confidential Treatment Requested 

  
 11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}]]